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Abstract 
 
Globally, the population of vertically HIV-infected young adults is increasing. The 
effect of vertically acquired HIV infection on B cell development and adaptive 
immunity is relatively unexplored. HIV infection is known to result in perturbations 
in B cell turnover and signalling, reflecting an accelerated drive to terminal 
differentiation. Whilst control of HIV load with ART is generally reported to result 
in recovery of normal B cell dynamics, persistent damage to memory B cell 
populations is well described and generation of new memory responses may remain 
impaired.  
 
This thesis explores how the development of B cell memory and the immune 
response to pneumococcus is altered when ‘immune education’ in early life occurs in 
the context of vertically acquired HIV infection. Young adults with vertically 
acquired infection were compared with those infected horizontally in early adulthood 
and with healthy adults.   
 
HIV infection was associated with expanded populations of abnormally activated 
and immature B cells compared to healthy controls. Vertically infected patients 
showed decreased marginal zone and switched memory populations compared to the 
horizontally infected group, especially in those patients with controlled HIV viral 
load. HIV-infected patients showed impaired baseline anti-pneumococcal immunity 
and diminished humoral responses to immunisation with the pneumococcal 
polysaccharide vaccine, with a trend to lower antibody concentrations in the 
vertically compared to the horizontally infected population. There was some 
suggestion of benefit of early sustained viral control in the vertically infected group.  
 
In those patients infected with HIV from early childhood, damage to B cell memory 
populations and impairment of generation of humoral immunity to pneumococcus is 
evident in early adult life. It appears likely that viral control in early childhood may 
help to limit this damage.  
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Chapter 1. Introduction 
 
1.1 Growing up with HIV: the scale of the problem 
 
Approximately 34 million people are infected globally with the human 
immunodeficiency virus (HIV) and in 2012, approximately 1.6 million of these were 
aged 12-24 years [1]. Most of these young people live in sub-Saharan Africa, but the 
UK is home to nearly 1800 children with HIV [2], of whom about a third are aged 15 
years or older.  
 
Young people with HIV comprise both those infected by the horizontal route (sexual 
or blood product transmission) and those infected vertically from their mother in 
utero and/or at the time of parturition. The rate of horizontal infections in young 
people remains high worldwide: in 2010, young people aged 15–24 years accounted 
for 42% of new HIV infections in people aged 15 years and older [3]. Vertical 
infection remains a global concern although transmission rates are reportedly 
reducing; in 2011, 330,000 (280,000–390,000) children acquired HIV infection. This 
represents a 43% decline since 2003 and a 24% reduction since 2009 [4].  
 
Mortality rates for individuals infected by HIV have reduced significantly with the 
advent of effective antiretroviral therapy. In 2011, about 1.7 million people died 
from AIDS-related causes worldwide. This represents a 24% decline in AIDS-related 
mortality compared with 2005 (when about 2.3 million deaths occurred), despite 
increasing prevalence of the infection [4]. This improved survival, coupled with high 
rates of vertical transmission in the previous two decades, has resulted in increasing 
numbers of young adults who have been infected with HIV since birth. In the UK, 
the age distribution of the national cohort of paediatric HIV-infected patients has 
changed considerably over the years.  In 1996 the median age was 5.1 years (range, 
0-11 years); by 2013 it was 13.3 years (range, 0-22 years).  Similarly, the proportion 
of the cohort aged ≥15 years increased from <1% in 1996 to 31% in 2013 [2].  
 
This cohort of vertically infected young adults is likely to continue to increase 
worldwide as effective therapy (antiretroviral therapy; ART) becomes more widely 
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available and survival rates continue to increase as a result. As these children reach 
adulthood, their care will be transitioned from paediatric to adult services. In the UK, 
382 young people left paediatric care and transitioned to adult clinics by 2011, with 
approximately 50 transferring each year between 2007 and 2011, at a median age of 
17.6 years [2]. This population of vertically infected young adults remains poorly 
characterised from an immunological perspective, and there is little data to inform 
clinical decisions regarding such issues as drug treatment, immunisation, long term 
prognosis and likely medical needs.  The impact of HIV infection on the developing 
immune system is not well understood, and it has not previously been possible to 
examine the long term effects due to poor survival rates. Unlike their horizontally 
infected counterparts, who have acquired HIV infection at a time of immunological 
maturity, these young adults have grown up with HIV, and the early development 
and education of their immune system has occurred in the context of this chronic 
infection. No direct comparison has been performed to date of the immunological 
impact of HIV infection on these two distinct patient groups.  
1.2 The immune effects of HIV infection  
 
The human immunodeficiency virus (HIV) is a retrovirus which infects a variety of 
immune cells, including CD4
+
 T cells, macrophages and dendritic cells. Infection of 
cells with HIV results in conversion of viral RNA to viral DNA, which becomes 
integrated into the host cell genome. Transcription of viral DNA to messenger and 
genomic RNA by host cell RNA polymerases results in synthesis of HIV virions, 
which bud out of the cell and infect other cells. Primary infection is associated with 
high levels of virus propagated within lymphoid organs, predominantly CD4
+
 T 
cells. Expansion of virus-specific cytotoxic CD8
+
 cells usually results in a degree of 
viral control with stabilisation of CD4
+
 cells. Ultimately, however, without 
treatment, destruction of CD4
+
 T cells results in immunodeficiency, susceptibility to 
opportunistic infections, and progression to AIDS and death [5].  
 
1.3 HIV infection and B cells 
 
HIV infection has thus traditionally been considered to be a T cell disease, with 
CD4
+
 cells the primary target [6]. Despite this focus on T cell involvement, HIV 
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infection results in dysregulation and dysfunction of all major lymphocyte 
populations, in addition to myeloid cells which are involved in innate immune 
responses and bridging the gap between innate and adaptive immunity. Effects of 
HIV infection on B cells have been described even before the CD4
+
 cell depletion 
becomes evident [7,8]. Polyclonal B cell hyperactivity [7] with resulting 
hypergammaglobulinaemia [9], autoimmunity [10] and an increased incidence of B 
cell malignancy [11] were all documented early in the epidemic. Although defective 
T cell help in selection of high affinity B cells and generation of plasma cells may be 
implicated to some extent, the evidence for independent effects of HIV on B cell 
development and function has become clear.   
 
The effects of HIV infection on B cells are thought to reflect a combination of direct 
interactions of the virus with B cells and indirect interactions that are associated with 
a wide range of systemic alterations (Table 1.1). Uncontrolled viral replication 
causes perturbations in B cell turnover and signalling, reflecting an accelerated drive 
to terminal differentiation, possibly through aberrant or poorly regulated 
developmental pathways [12].  
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Mechanism 
 
Effect 
 
References 
 
Direct effects of HIV on B cells 
 
Binding of HIV envelope 
glycoprotein gp120 to B cells 
expressing VH3 genes 
(superantigen-like binding) 
 Widespread functional activation of a large proportion of 
the B cell repertoire, with consequent clonal deletion  
 May explain increased incidence of secondary infections 
with specific pathogens 
[13-21] 
 
Interaction between 
complement receptor CD21 
and complement proteins 
bound to opsonised HIV 
virions 
 Enhanced infectivity of target CD4+ T cells as  opsonised 
HIV is transferred to activated T cells 
 May activate B cells directly by engagement of  CD21   
[22-25] 
 
 
Indirect effects of HIV on B cells 
 
Generalised activation by: 
 Increased systemic 
cytokine concentrations 
eg  interleukins, IFNα, 
type I IFN 
 Increased bacterial 
translocation from the 
gut into the blood (ie 
chronic/intermittent 
subclinical infection) 
 Excess immunoglobulin 
production  
 Hypergammaglobulinaemia  
 Increased autoantibodies  
 Increased expression of activation, proliferation, and 
terminal differentiation markers on circulating B cells 
 Increased turnover, reflecting increased activation and 
drive towards terminal differentiation 
 Appearance of apoptosis-prone subpopulations of B cells 
with increased apoptosis contributing to depletion of 
circulating B cell subpopulations 
 Exhaustion leading to altered migration, proliferation and 
effector function 
 Functional implications including hyporeactivity to 
ligation of the BCR to stimuli and impaired T cell 
interaction by reduced co-stimulatory ability 
 Excess immunoglobulin production results in formation of 
immune complexes with activated cells, triggering 
secretion of inflammatory factors 
 
[7,26-
29,29-
46,46-48]  
 
[49] 
 
[41,50-55] 
 
Reviewed 
in [12] 
 
[26,46] 
 
[29] 
Altered B cell trafficking 
 
 Impaired migration from periphery to secondary lymphoid 
tissue (important for generation and maintenance of 
immune memory: germinal centre reaction including class 
switching, somatic hypermutation and affinity maturation, 
leading to differentiation to memory and plasma cells)  
[51,56-59] 
Table 1.1. Direct and indirect effects of HIV on B cells. 
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1.3.1 Direct effects of HIV on B cells 
 
Direct effects of HIV on B cells were reported early in the pandemic [60] although 
there is little evidence that HIV can productively replicate in B cells in vivo. The low 
frequency of B cells directly interacting with HIV virions through the B cell receptor 
as compared to the degree of B cell dysregulation in HIV infection suggests that 
indirect effects may be more significant.  There is, however, strong evidence that 
HIV binds to B cells in vivo.  
 
The HIV envelope glycoprotein gp120 is known to bind B cells expressing variable 
region three (VH3) immunoglobulin genes. This VH3 gene family, with 22 
functional genes, constitutes the largest of the seven families of functional gene 
segments at the human VH locus, and comprise about half of the expressed VH 
repertoire in adult peripheral B cells [61-65]. VH3 antibodies are crucial for defence 
against a variety of bacterial [66,67] and viral [68,69] pathogens, including bacterial 
polysaccharide antigens found in Streptococcus pneumoniae [70] and Haemophilus 
influenzae [71]. Goodglick et al.  [14] determined the epitope on gp120 responsible 
for its binding activity, while Karray and colleagues [15] identified the sequence 
motifs involved in the binding process and later demonstrated that gp120 binding is 
restricted to immunoglobulins from the VH3 gene family [16].  
 
Gp120 binds VH3 immunoglobulins in a non-classical, “superantigen-like” 
interaction outside the normal antigen-binding pocket [13]. This superantigen-like 
binding results in widespread functional activation of a large proportion of the B cell 
repertoire. As seen with other superantigens, including Staphylococcus aureus 
protein A (reviewed in [72]), this may result in the transient clonal expansion shown 
by Chong and colleagues [73] in HIV-infected patients and the development of 
hypergammaglobulinemia. Superantigen activation has been shown in mice [74] to 
result ultimately in clonal deletion leading to a long lasting clonal deficit. In 2007, 
using mice genetically engineered to express human antibodies,  Viau [75] showed 
that soluble gp120 induced both depletion of B-1a cells (considered to be represented 
in man as innate germline IgM producing B cells) and a functional alteration of the 
humoral response to a protein antigen (tetanus toxoid), suggesting impact on both the 
innate and adaptive B cell response.  Several reports have suggested a similar 
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depletion of VH3-expressing B cells in humans during the late stages of HIV 
disease. Berberian [76] demonstrated a specific deficit of VH3
+
 B cells in 19 patients 
with HIV, compared to healthy controls [19,20,76]. In 1994, the same group [17] 
showed, in a cross-sectional clinical study, that VH3-expressing B cells were 
elevated in early HIV infection but depleted in those with AIDS, again consistent 
with a superantigen-like early activation resulting in eventual depletion of cell 
populations expressing these important genes.  These VH3-expressing cells are 
preferentially expanded in memory B cell populations. Their absence in HIV 
infection may suggest that, in addition to depletion by superantigen activation, gp120 
binding may impair B cell maturation with the failure to establish VH3-expressing 
memory cell populations. Scamurra et al. [21] showed in HIV patients that there was 
no change in VH3 expression in IgM or IgD mRNA from peripheral B cells (likely 
to be predominantly naïve cells), but that VH3 family expression in IgG mRNA, 
representing immunoglobulin secreted by memory cells, was reduced. Other studies 
[20], however, have showed a drastic under-representation in vivo of VH3
+
 
immunoglobulin expressed by IgM
+
, and naïve B cells, as well as by IgG
+ 
cells, in 
patients with HIV and low CD4
+
 counts. It has also been shown that switched 
memory B cells from HIV-infected patients show decreased mutation frequencies, 
especially in antigen-binding VH3 CDR genes [77], and that HIV infection is 
associated with selective defects in immunoglobulin gene utilization [78] which may 
have significant implications for the humoral memory response. 
 
The advent of highly active antiretroviral therapy (HAART) has allowed changes in 
immune profiles to be related to HIV viraemia and disease control. Initiation of ART 
has been shown to result in normalisation of antibody repertoire [79] and a restored 
ability to produce antibody from VH3 B cells [80], which may be consistent with the 
findings discussed previously [21] suggesting that the naïve B cell repertoire may be 
relatively unaffected compared to that of memory cells. Juompan et al. [81] 
confirmed an inverse relationship between VH3 antibody levels and viral load. 
Elkins [82] also assessed the early effect of HIV infection on the integrity of the 
peripheral B cell repertoires and showed an inverse association between viraemia 
levels and B cell repertoire integrity.  
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The presence of clonal deficits within the antibody repertoire in uncontrolled HIV is 
likely to have significant functional consequences. The selection of specific VH 
genes, which are subsequently linked to specific diversity (D), and joining (J) region 
genes, is a principle determinant of the structure of the antigen binding site [83] and 
thus diversity. Loss of clones, each with a specific antigen binding site, has 
consequences for functional immunity, as shown by previous structure-function 
correlations of human monoclonal antibodies specific for pneumococcal (Pnc) 
antigens [84]. Deletion of clones bearing specific V gene-encoded immunoglobulins, 
particularly the VH3 family which is important for many bacterial and viral antigens, 
as stated previously, will negatively impact upon the ability of the individual to 
recognise and control pathogens. There is evidence for a link between 
immunoglobulin repertoire defects and disease susceptibility:  the light chain allele 
VkA2 encodes A2
+
 antibodies, which have  high avidity to the capsular 
polysaccharide of Haemophilus influenzae type B, and are absent  in a population 
that has a significantly increased incidence of infection with this pathogen [85]. VH3 
is the largest family of variable genes and many of the pathogens against which an 
effective immune response depends on VH3 genes are commonly found in HIV-
infected patients. Deletion of VH3-expressing B cells as a direct consequence of 
viral binding may therefore contribute to HIV-associated humoral immune 
dysfunction and to the increased incidence of secondary infections observed in these 
patients. 
 
In addition to gp120-mediated interaction through VH3 genes, direct action of HIV 
on B cells is also thought to occur through interactions between the complement 
receptor CD21, expressed on most mature B cells, and complement proteins bound 
to opsonised HIV virions [22,23]. This binding may result in enhanced infectivity of 
target CD4
+
 T cells, as opsonised HIV has been shown to be passed to activated T 
cells [23] and may also affect B cell responses directly by engagement of  CD21  
[86]. 
1.3.2 Indirect effects of HIV on B cells 
Activation 
Non-specific immune activation is a hallmark of HIV disease and has been long 
recognised in B cells [32,34,35,87]. The direct effect of HIV binding in triggering 
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superantigen-like activation has been discussed. Other HIV proteins, including the 
regulatory protein, Nef (Negative Regulatory Factor) [39,40], and pro-inflammatory 
cytokines, including interferon-α [30] are also known to activate B cells. Increased 
bacterial translocation through the gut in HIV infection may also contribute to non-
specific B cell activation [88].  
 
The first comprehensive analysis of HIV-induced B cell hyperactivity was performed 
by Shirai et al. in 2001 [33]. Since then, the hyperactivation of B cells in HIV 
infection has been well characterised. The subpopulations of B cells responsible for 
increased immunoglobulin secretion have been proposed to be both hyperactivated 
naïve B cells [89] and an abnormally expanded B cell subpopulation expressing low 
levels of CD21 [45], which may be responsible for producing autoreactive antibodies 
[10,33,59,90]. Circulating B cells themselves show increased expression of 
activation, proliferation, and terminal differentiation markers [7,28,33,45,46,89]. 
This increased expression of activation markers has been shown by some studies to 
correlate inversely to disease control [51,55] and is largely reversible by HAART 
[28,41,46,52,55,91], though Regidor et al. [92] showed that the reduction in serum 
cytokines achieved after ART was only partial, with evidence of persistent 
hyperactivation still evident several years after therapy initiation.   
 
Hyperactivation has important implications for B cell dynamics, resulting in 
disturbances in B cell subpopulations (see Table 1.3) including increased turnover 
[41,93] apoptosis [41], and B cell dysfunction (discussed later).  
 
Chronic B cell activation ultimately results in exhaustion, with consequent reduced 
function and depletion of cell populations. The “exhausted cell phenotype” has been 
extensively described (reviewed in [12]). Exhausted cells express high levels of 
inhibitory receptors [94,95], and altered expression of homing receptors resulting in 
abnormal migration of cells to lymph nodes [59,96]. Proliferative responses are 
reduced [47,97] and effector function may be impaired [59]. 
Altered turnover and increased B cell death 
Increased cell turnover in HIV infection is well established [49,93]. This tendency to 
increased turnover is likely to reflect the increased activation and drive towards 
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terminal differentiation, and is likely to contribute to the increased emergence of B 
cell subpopulations prone to apoptosis [41,52,53]. Samuelsson [98] showed elevated 
levels of B cell apoptosis in all HIV-infected individuals compared with seronegative 
control subjects, with a tendency toward increased levels of apoptosis with 
progressive disease, and a positive correlation with viral load. Ultimately, this is 
likely to lead to depletion of B cell subpopulations [99] from peripheral blood. 
Equivalent change has been demonstrated in lymph node tissue [100].  Intrinsic and 
extrinsic pathways of apoptosis are both affected by HIV infection [53]. Activation 
of the intrinsic apoptosis pathway is associated with the under-expression of bcl-2, a 
“survival gene” which encodes an anti-apoptotic protein which blocks programmed 
cell death [101]. Expression of a bcl-2 transgene has been shown to rescue pre-B and 
immature B cells from cell death indicating that bcl-2 can inhibit the apoptotic cell 
death of progenitors and early B cells, and overproduction of bcl-2 protein prevents 
the death of B cells cultured in vitro [102,103]. In HIV infection, bcl-2 expression 
has been shown to be reduced on some B cell subpopulations, possibly reflecting 
increased susceptibility to intrinsic apoptosis [51,52]. Proneness to intrinsic 
apoptosis in B cells in HIV infection may also be partly due to skewing of the B cell 
populations as a result of hyperactivation, including an overrepresentation in HIV 
viraemia of immature B cells which are highly susceptible to intrinsic apoptosis [53].  
 
The extrinsic pathway is activated by triggering of a death receptor [104], Fas, also 
known as CD95. In HIV infection, CD95 is the most overexpressed death receptor 
on the B cells of HIV-viraemic individuals, as determined by DNA microarray 
analysis [41].  The extrinsic pathway is often considered to be involved with removal 
of activated immune cells after they have performed their function or as a result of 
incomplete or inappropriate activation [105] and expression of CD95 seems to be 
increased in activated cells [41], providing further support to the hypothesis that 
activation contributes to the increased apoptosis seen in HIV infection. There may 
also be a role for the lymphopenia-induced cytokine IL-7 in the increased B cell 
apoptosis observed in HIV infected individuals, via an indirect mechanism involving 
the induction of IFN-ϒ in T cells, which leads to consequent upregulation of CD95 
on B cells [106]. The intrinsic and extrinsic pathways are not entirely distinct: the 
expression of bcl-2 is believed to regulate the extrinsic apoptosis pathway by 
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prevention of mitochondrial disruption and subsequent caspase activation - one 
subtype of the Fas-mediated apoptotic pathway [107].  
 
Altered B cell trafficking 
In addition to adverse effects on B cell turnover and cell death, HIV infection has 
also been shown to result in derangement of lymphocyte migration and recirculation 
between the periphery and lymphoid tissue, which are critical for the development of 
effective immunity. These interactions are largely regulated by the interaction of 
chemokine receptors on lymphocytes with the expression of their respective ligands 
in different tissue compartments [108,109]. Antigen-stimulated B and T cells migrate 
from the periphery to secondary lymphoid tissue [110], resulting in a germinal centre 
(GC) reaction where class switching, somatic hypermutation and affinity maturation 
occur, leading to differentiation to memory and plasma cells [111]. 
 
The G-protein coupled chemokine receptor, CXCR5, is an important receptor in 
recruiting B cells to lymph nodes for maturation of T cell-dependent B cell responses 
and, with another chemokine receptor, CXCR4, is important for the organisation of 
the GC microarchitecture [112,113]. The chemokine CXCL13 is the ligand for 
CXCR5, and is produced by follicular dendritic and stromal cells within lymphoid 
tissues including the spleen, lymph nodes, gut and liver. Ligation of CXCL13 by 
CXCR5 is important in regulation of B cell organisation within the lymph node 
follicle. Upregulation of CXCR5 on B cells, therefore, promotes increased ligation 
by CXCL13, resulting in homing to the B follicle to allow a germinal reaction to 
take place (reviewed in [114]).  Altered homing to lymphatic tissue due to changes in 
trafficking receptors has been long described in HIV infection [56,57]. This altered 
homing is thought to involve altered CXCR5 expression by B cells in HIV 
[51,58,59], with possible negative consequences for the establishment of GC 
reactions. Other migration pathways, including CXCL12-CXCR4/7 mediated 
migration [115] may also be affected by the increased activation of B cells in HIV 
infection. 
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The key effects of HIV on the behaviour of B cell subpopulations in terms of 
apoptosis, cell trafficking and cell turnover, and the markers used to examine them, 
are shown in Table 1.2.  
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Behaviour and markers 
used 
Function Change in HIV References 
Intrinsic apoptosis: bcl2 
• Anti-apoptotic protein which blocks programmed 
cell death  
• Expressed differentially at different stages of B 
cell development 
• Used as a marker of susceptibility towards 
intrinsic apoptosis  
Decreased in 
some B cell 
subpopulations 
[51-53,55] 
Extrinsic apoptosis: 
CD95 (Fas) 
• “Death receptor” triggering apoptosis via 
extrinsic pathway 
• Used as a marker or susceptibility towards 
extrinsic apoptosis 
Increased in 
most B cell 
subpopulations  
[41,51-
55,116] 
Trafficking: CXCR5 
• Chemokine receptor binding CXCL13 
• Important receptor in recruiting B cells to lymph 
nodes for maturation of T cell-dependent B cell 
responses  
• Used as a marker of B cell trafficking 
Decreased in 
many B cell 
subpopulations 
[58,59] 
Turnover: Ki67 
• Nuclear protein 
• Cell cycling marker  
• Used as a marker for cell turnover 
Increased in 
some B cell 
subpopulations 
[41,53] 
Table 1.2. Key B cell surface markers used to examine the behaviour of B cells in HIV 
infection. 
 
Impact of HIV on peripheral B cell subpopulations 
As discussed, abnormal activation, turnover, differentiation, trafficking and 
apoptosis result in profound skewing of B cell populations in the peripheral blood. 
Although analysis of peripheral subpopulations cannot be considered necessarily to 
reflect exactly the status of the B cell compartments of the bone marrow and lymph 
tissue, the altered distribution in the blood nonetheless may give an indication of the 
likely degree of disruption to B cells overall. Since different immune cells have 
different functions and variable susceptibility to apoptosis, it is evident that 
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alterations in the composition of the B cell population as a whole, in addition to the 
direct effects of HIV infection, will impact on overall B cell survival, function and 
repertoire. 
 
 
There are numerous challenges in the evaluation of the effects of HIV infection on B 
cell subpopulations. Varying definitions of B cell subsets can result in confounding 
and contradictory results. Even in healthy HIV-negative individuals, there is a wide 
range of circulating B cell frequencies [117] so a large number of participants and/or 
longitudinal analyses are required to describe disease-related changes. There is also a 
high likelihood that memory B cells in tissue compartments are as important to 
consider as those circulating in the peripheral blood, although more difficult to study. 
Nonetheless, substantial evidence has accumulated during the past two decades for a 
significant impact on HIV infection on distribution of B cell subsets in the peripheral 
blood, with emergence of several abnormal B cell subpopulations and significant 
depletion of other normal cell populations.  
 
The drive towards terminal differentiation is reflected in a general trend towards a 
reduction of effective mature populations, with an emergence of abnormally 
activated and exhausted populations, and a compensatory increase in immature and 
transitional B cells emerging from the bone marrow. These peripheral B cell 
subpopulation changes are described in Table 1.3 and are discussed more fully in 
Chapter 3.  Memory populations, including both classical and marginal zone 
memory (discussed more fully in section 1.4.1) appear to be particularly (and 
possibly irreversibly) damaged in HIV infection [118,119]. Figure 1.1 shows the 
relationship of the various B cell subpopulations to one another.  
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Figure 1.1. Schematic diagram showing the B cell subpopulations studied in the peripheral 
blood.  
Markers used to identify these populations are shown in Table 2.5, Chapter 2. This figure is partially adapted 
from Moir et al. 2009. 
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Populations 
Description Change in 
HIV infection 
References 
Naïve cells 
 Mature, CD27- B cells which have not 
previously encountered antigen  
 Unmutated IgV region  
Decreased/ 
increased;– 
effect not clear 
[48,51,120,121] 
Marginal zone 
memory (MZM) 
cells 
 Type of memory cell expressing CD27 
and IgD. Predominantly secretes IgM 
which is somatically mutated.  
 Thought to be generated in marginal 
zone of the spleen in the absence of a 
germinal centre reaction.    
 Play a major role in the immediate 
response against encapsulated bacteria 
 May be important in facilitating 
adaptive humoral response 
Decreased 
 
[118,119] 
Switched memory 
cells 
 Circulating CD27+ memory cells which 
have undergone somatic hypermutation 
in the germinal centre following antigen 
exposure  
Decreased [55,116,118,120,122] 
Recent bone 
marrow emigrants 
(BME) and 
transitional cells 
 Cells thought to be at an early stage in 
mature naïve B cell maturation  
 Normally scarce in peripheral blood 
Increased [53,54,119,123-126] 
Plasmablasts  Short lived cells, believed to be 
antibody-secreting precursors of long-
lived bone marrow plasma cells 
 Found with low frequency in peripheral 
blood  
Increased [41,45,127] 
CD21lo cells  Present at low frequency in healthy 
individuals 
 Known to increase in disease states of 
chronic immune activation 
Increased  [45,59] 
Mature activated 
cells 
 Described in the context of HIV as 
CD27+ CD21lo; a mature B cell showing 
features of abnormal hyperactivation 
Increased [41] 
 
Exhausted cells  Described in the context of HIV as 
CD27- CD21lo, displaying features of 
immune exhaustion, including shortened 
replication history, reduced 
immunoglobulin diversity and poor 
proliferative responses 
Increased  [59] 
 
Table 1.3. Changes to B cell subpopulation distribution in adults in HIV infection. 
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1.4 Disrupted immunological memory in HIV 
 
Immunological memory is defined by the ability of the immune system to respond 
more effectively to pathogens previously encountered either through infection or 
immunisation. The damage to memory subpopulations of B cells in HIV infection, in 
conjunction with other mechanisms of disruption, results in profound impairment of 
the generation of immune responses, both to infection and immunisation.  
1.4.1 Normal generation of immune memory 
 
Memory cells are defined as antigen-experienced cells which have generally 
undergone clonal selection and a degree of affinity maturation (through somatic 
mutation). They are pre-primed to generate a rapid and specific response (reviewed 
in [128]). A classical memory B cell can be defined as a long lived, antigen-
experienced, clonally selected B cell that can rapidly differentiate into a plasma cell 
on re-exposure to antigen [129], enabling production of high affinity, antigen-
specific antibodies [130-133]. Classical memory cells have undergone T cell-
dependent somatic hypermutation and some have also undergone immunoglobulin 
class switching [128,134] in the germinal centre of the lymph node.  
 
However, memory B cells are more heterogeneous than initially understood. In 
addition to the classical memory cells described above, memory responses 
originating through GC-independent pathways, without the cognate help of T cells, 
also exist. These cells are reported to have specificity for polysaccharide antigens. 
These B cells are found in the marginal zone (MZ) of the spleen (reviewed in [135]) 
and can be identified in the peripheral blood through IgD
+
 (and generally IgM
+
) 
CD27
+
 expression [136,137]. These IgM/IgD memory cells (hereafter referred to as 
marginal zone memory (MZM) cells), can be generated in the absence of GCs [138] 
and are thought to have undergone less proliferation than GC cells [139] with fewer 
somatic mutations [134] and immunoglobulin production which has, in the main, not 
switched to isotypes other than IgM [136]. It is not clear whether or not somatic 
mutation in these cells is antigen-driven [136,140]. These cells are thought to 
generate a rapid, relatively high-affinity IgM response to encapsulated bacteria in 
early infection [141]. They represent a functional intermediate between innate and 
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acquired immunity, and facilitate rapid bacterial clearance from the blood [142]. 
Human MZ B cells develop progressively over the first two years of life, and their 
absence in early childhood may contribute to explaining the particular 
unresponsiveness of infants to polysaccharide vaccines [143] as both the cells and 
the antibody they produce are thought to be important in facilitating the induction of 
adaptive humoral immunity.  
1.4.2 Immune responses to pneumococcal infection 
 
Streptococcus pneumoniae is a Gram-positive encapsulated diplococcus, whose 
polysaccharide capsule is an essential virulence factor for invasive pneumococcal 
(Pnc) disease (IPD). There are about 90 Pnc serotypes, based on differences in the 
capsule composition. Globally, about 20 serotypes are thought to cause the majority 
of invasive disease. The bacteria are transmitted by colonised or infected respiratory 
secretions. Whilst Pnc colonisation is common, most colonisation does not result in 
invasive disease although colonisation is considered a pre-requisite for infection. 
Disease occurs when the bacteria spread systemically, either by aspiration to the 
lungs or migration to the blood. The young and old are particularly vulnerable and 
Pnc disease is believed to cause about a million deaths annually worldwide [144].  
 
The humoral immune response to S. pneumoniae infection is provided by pre-formed 
“natural” or innate IgM antibodies, the MZM B cell population and the classically 
generated memory B cell population.  The early immune response is thought to be 
mediated primarily by MZM memory B cells, for which Pnc polysaccharides are 
dominant target antigens [145], with rapid generation of IgM which binds Pnc 
directly. In splenectomized and asplenic patients, it has been shown that the absence 
of MZM memory B cells is correlated with low-absent anti-polysaccharide IgM 
antibodies and increased susceptibility to pneumococcal infection [145]. This 
relationship has also been described in other unrelated immunodeficiency diseases. 
A loss of MZM B cells is associated with increased incidence of bacterial pneumonia 
in patients with common variable immune deficiency (CVID) [146] compared to 
patients who retain this B cell population. This MZM-mediated response is thought, 
in itself to result in poor generation of memory cells and minimal long lasting 
immune memory. However, as discussed in Section 1.4.3, MZM B cells are also 
thought to be important in facilitating the development of the classical IgG 
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dominated antibody response, probably by binding of Pnc antigens to complement 
fragment C3d allowing immediate localisation to follicular dendritic cells in the 
germinal centres, where isotype switching and affinity maturation can take place 
(reviewed in [147]) generating lasting immune memory.  
 
Serotype-specific antibody, mainly of IgG isotype [148,149], generated by the 
classical memory pathway, provides the lasting protection against Pnc disease. This 
antibody is both directed against the capsular polysaccharides and protein antigens 
located underneath the capsule, such as the bacterial-derived protein PspA, the 
lipoprotein PsaA, and the cell-wall component teichoic acid. Once opsonised by 
antibody, the bacterium is eliminated mainly by opsonophagocytosis, as the 
complement-resistant polysaccharide capsule protects against extracellular 
complement-mediated killing. Protective levels of antibody are thought to be 
maintained by either repeated colonisation or through bystander activation of 
existing memory populations [150,151]. Nasopharyngeal colonisation, and possibly 
invasive infection, appears to result in PPS-specific antibody production [152,153]). 
60% of healthy children will have been colonised with one or more capsular 
serotypes of pneumococcus by 1 year of age [154], and it is unclear whether the 
immune response to immunisation in later life represents a primary or secondary 
immune response.  
 
Other factors such as local and splenic-resident macrophages and interleukin (IL)-
17-producing CD4
+
 T cells in the lung and mucosal associated lymphoid tissue also 
play an important role in regulating protection against Pnc disease [155].  
 
Vaccines against Pnc include both the pneumococcal polysaccharide vaccine (PPV) 
and the pneumococcal conjugate vaccine (PCV). PPV is a polysaccharide vaccine 
and is considered to induce a primarily T cell-independent response, mediated by 
naïve B cells, MZM memory population, and pre-existing switched memory to 
polysaccharides. PCV consists of polysaccharide conjugated to a protein carrier, and 
thus recruits cognate T cell help to induce a classical memory response, and is 
considered to generate lasting immune memory. 
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1.4.3 Impact of HIV infection on generation of immune memory 
Increased risk of infection 
Impaired immune response with abnormal generation and maintenance of immune 
memory results in increased susceptibility to a variety of infections in HIV-infected 
patients. It has long been clear that patients with HIV infection are at higher risk of 
bacterial infection [156,157]. Early studies showed the role of B cell dysfunction in 
this susceptibility, with increased serum IgE and IgA levels in those patients 
experiencing increased frequency of opportunistic infection, even once their CD4
+
 
count had been restored by ART [158]. 
 
Streptococcus pneumoniae is a clinically important pathogen in HIV infection. 
Defective immunity to pneumococcal infection in HIV-infected individuals 
manifests clinically both in increased incidence of IPD and impaired response to 
immunisation with pneumococcal vaccines. The incidence of pneumococcal disease 
is reported to be up to one hundred times greater in HIV-infected patients than in the 
general population [159,160] and pneumococcal infection is the commonest cause of 
pneumonia in HIV [161]. The effect of ART on this increased susceptibility to IPD 
remains controversial. Some studies have demonstrated a positive impact [162,163], 
but this finding has not been replicated elsewhere [164,165] and any protective effect 
is unlikely to reduce rates in invasive disease to those seen in the HIV non-infected 
population [166,167]. Since the introduction of pneumococcal conjugate vaccines 
(PCVs) which have been associated with reduced population carriage of common 
disease serotypes and reduced prevalence of IPD amongst HIV-infected and non-
infected adults [168,169] it has been more difficult to determine the effect of ART 
on protection against Pnc disease. 
 
Defective generation and maintenance of immune responses in HIV infection 
The drive in HIV infection towards hyperactivation, terminal differentiation and 
apoptosis, combined with the consequent skewing of B cell subpopulations away 
from effective mature populations and towards immature and exhausted populations 
is likely to result in significant impairment in the ability to generate immune memory 
responses of both classical and MZM type and to maintain protective antibody levels 
to previously encountered antigens [118,170].  
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In order to generate an effective memory response, of either classical or marginal 
zone type, it is necessary for naïve cells to generate de novo immune responses to 
antigen [51]. This ability may be impaired in HIV infection, possibly as a 
consequence of hyperactivation, depletion of B cell subpopulations, and, perhaps, 
clonal deletion of VH3 gene families, as previously discussed. Naïve cells have been 
shown to proliferate poorly in response to stimuli in HIV infection [47], perhaps as a 
result of diminished TLR9 mRNA expression, and abnormal B cell responses to T 
cell-independent polyclonal B cell activators were demonstrated early in the 
epidemic [7,8,87], with hyperactivation of B cells associated with  ex vivo 
hyporeactivity of B cells on in vitro stimulation [26].  
 
Altered B cell function will also impact on T-dependent antibody responses and 
possible cell mediated immunity as B cells are very efficient cognate antigen 
presenting cells [114] and in HIV infection, they appear to be less able to provide 
stimulatory signals to CD4
+
 T cells following MHC-II mediated antigen presentation 
[46]. Additionally, T cell help normally provided to B cells is defective in HIV 
infection as a result of impaired interaction between CD40 and CD40 ligand, 
associated with impaired expression of CD25 in response to activated T cells, and 
consequent reduced proliferative response to IL-2. [48]. Poor T-B interaction is seen 
early in infection before functional and quantitative defects in T-helper activity are 
seen, and it is not reversed in vitro by addition of normal CD4
+
 T cells ([8,171]. 
 
The increased susceptibility to infection, including to Pnc disease, in HIV is 
associated with an impaired antibody response to both protein and polysaccharide 
antigens [7,32,172]. The deficit of marginal zone memory cells in adults, involved in 
response to polysaccharide antigens, is not reversed by ART [119]. This deficit is 
likely to be of considerable importance in contributing to the impaired natural 
immunity to S. pneumoniae seen in HIV infection [121,173] and is associated with 
poor immunological memory to immunisation with PPV [119], which is well 
documented in HIV infection (reviewed in [174]). Defects in MZM memory have 
also been related to susceptibility to other infections in HIV-infected patients [175]. 
  
Although depletion of classical memory populations in HIV infected individuals 
remains controversial [116,118,121,122], the impaired generation of classical 
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memory immune responses is likely to account for the poor serological response to 
many protein antigens, occurring both naturally and in vaccines. Reduction in 
pneumococcal protein antigen–specific memory B cells and in plasma anti-Pnc IgG 
titres has been demonstrated in HIV-infected adults [121] [173] and children [176] 
[177]. This is evident even during primary HIV infection, suggesting that subtle 
early alterations to B cell function may be important even prior to their depletion 
[52]. Reduced antibody levels to other naturally acquired bacterial [178,179] and 
viral [89,180] infections have also been shown in HIV infection; this has been shown 
in some studies to correlate with low memory B lymphocytes [89].  
 
Response to immunisation with protein antigens is impaired [170,173,181-183]. 
PCV vaccine response is also thought to be reduced in HIV infection and most 
studies demonstrate impaired antibody response in HIV-infected individuals 
compared to healthy controls [184,185]. One possible explanation is the reduced 
capacity of memory cells to produce IgG and IgM anti-pneumococcal antibody, 
shown in vitro in response to B cell polyclonal stimulation [173]. Nonetheless, use of 
the vaccine has been associated with a reduction in vaccine-serotype IPD in HIV-
infected adults even not on treatment [186]. 
 
The defects in both naturally and vaccine-induced Pnc-specific memory may be 
secondary to clonal deficits resulting from deletion of B cell clones expressing VH3 
genes, as discussed earlier, as pneumococcal antibodies are known to use this gene 
family [67,187]. Reduced B cell VH3 expression correlates to reduced anti-
pneumococcal antibody in HIV-infected adults [67]. Chang et al.  [187] showed an 
association between the anti-PPS response and the status of the VH3 repertoire, with 
impaired responses associated with abnormal repertoire shift in HIV-infected 
individuals. These changes were later shown to be reversible by effective ART [80].   
 
Impaired response to immunisation is, at least in part, due to a failure to maintain, as 
well as generate, an immune response. Malaspina [170] showed that despite similar 
numbers of antigen-specific antibody producing cells at one week after influenza 
immunisation, a significant difference in antigen-specific memory B cells was 
detected by day 54 between HIV-infected patients and healthy controls. This 
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suggests that HIV-infected patients are able to respond to immunisation but that the 
maturation and maintenance of a long-lived memory response is impaired.  
 
Furthermore, function of these antibodies, once generated, is also likely to be 
impaired in HIV infection, as seen by functional antibody studies performed in HIV-
infected children after immunisation with PCV [188]. Pneumococcal vaccine 
response in HIV infection is discussed further in Chapter 4. 
 
Relationship between MZM and generation of switched memory 
There is evidence that natural IgM memory, MZM and switched memory may be 
interrelated, particularly in the context of antibody responses to polysaccharides and 
encapsulated bacterial antigens, where secreted IgM and marginal zone memory is 
likely to be important in promoting the subsequent adaptive immune response. It is 
likely that MZ memory, activated early in pneumococcal infection, plays a 
significant part in rapid complement-mediated localisation of antigen to the spleen 
[189], where antigen-specific B cells are encountered and subsequently enter the GC 
reaction, resulting in generation of both switched memory populations and 
plasmablasts. Furthermore, it has been shown [190,191] that mice genetically 
deficient in secreted IgM produce less (and lower affinity) antigen-specific IgG than 
is seen in control mice, associated with fewer and smaller germinal centres. Reduced 
antigen trapping is also seen on splenic follicular dendritic cells, probably because 
antigen trapping is partially dependent on the deposition of activated C3 which is 
induced by IgM-antigen complexes. It is likely, therefore, that both natural and 
MZM-secreted IgM are important in facilitating the subsequent generation of IgG 
antibody from GC-derived switched memory cells for some infections. MZM 
depletion in HIV infection may, therefore, have implications for generation of 
classical memory responses, in addition to the accepted implications for marginal 
zone memory. 
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1.5 Effect of ART on B cells in HIV  
 
The effects of ART on HIV-related B cell changes in adults are summarised in Table 
1.4.  
 
 
Effect of ART 
 
Key References 
 
Normalisation of HIV associated changes 
 
 
Reversal of hypergammaglobulinaemia [192] 
Normalisation of antibody repertoire with restored ability to produce antibody from 
VH3 B cells 
[79-82] 
Partial reduction in activation markers expressed by B cells [28,41,46,51,52,91,92] 
Possible partial reduction in extrinsic apoptosis [41,51-55] 
Normalisation of Ki67 expression  [41]  
Normalisation of proliferation [47,97] 
Partial normalisation of B cell subpopulations (but probably not MZM or switched 
memory) and reduction in terminal differentiation 
[41,59,90,193] 
Controversial recovery of humoral immunity [119,170,173,194-
196] 
Early ART may reverse the reduction of both MZM memory B cells  and the switched 
memory B cell compartment  
[52,193] 
Early ART may result in improved memory B cell response  [193] 
 
Failure to normalise HIV associated changes 
 
 
Failure to completely restore switched memory populations [90,116,118,126] 
Failure to completely restore MZM populations [119] 
Failure to completely restore memory responses [119,170,173] 
Table 1.4. Effects of ART in adults on HIV-related B cell changes. 
 
The advent of effective ART since the mid-1990s has permitted study of the effect of 
slowing or reversing the HIV disease progression and isolation of the effect of HIV 
viraemia. Decrease in HIV viraemia with ART results in a decrease in B cell 
hyperactivation [28,52,197], and a normalisation of B cell dynamics including 
turnover [41], proliferation [47,97] and apoptosis [41,52,53]. Upregulation of genes 
associated with terminal differentiation have also been correlated with HIV viraemia 
and are thus reversible with ART [45]. It appears that these changes with ART result 
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in partial normalisation of the peripheral B cell subpopulations [59,90,193].  
However, the defect in both switched [55,59,116,118,120,126] and MZM [119] cells 
appears to persist despite effective treatment, with likely long term consequences for 
immune function. Some reports of improvement of humoral immunity against CMV 
and influenza in short-term treated patients [194-196] suggested that memory B cell 
responses may be restored by ART, but this has not been confirmed by subsequent 
studies [119,170,173]. As discussed above, the true impact of ART on susceptibility 
in HIV infection to IPD remains controversial.  
 
There are few comprehensive studies examining B cell numbers and function in 
HIV-infected individuals who initiate ART during the acute phase of infection. 
However, there are indications that damage to B cell function, including generation 
of memory responses, may occur early in HIV infection [52,173,192], which may 
imply benefit of early ART.  Some studies have suggested that early initiation of 
ART does seem to restore both MZM memory B cells [52] and the switched memory 
B cell compartment [193].  
 
 
1.6 HIV infection and B cells in children 
 
The impact of HIV infection on B cells in the paediatric population remains 
relatively unexplored, and virtually no published data exists in this field regarding 
the growing population of adolescents with vertically-acquired HIV infection.  
 
Hypergammaglobulinaemia has been demonstrated in children [9,198,199]. 
Reduction in B cell numbers and proportions has also been shown [9,200,201]. The 
impact of HIV infection on individual subpopulations in children has been examined 
in a limited number of studies. These results are somewhat contradictory and are 
non-longitudinal, with small cohort sizes and considerable variability in treatment 
status and viral control. However, work to date does suggest persistent abnormalities 
in B cell memory in the paediatric population, in particular, MZM populations 
[199,202]; the impact on naïve and switched memory populations is less clear 
[177,199,202].  
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Functional immune impairment, manifest as increased infection [203-205] and 
inadequate vaccine responses (reviewed in [203,206]), is also described in children 
with HIV. Impaired vaccine immunogenicity including generation and maintenance 
of memory has been described. Hepatitis B vaccine failure has been associated with 
poor virological control and CD4 lymphopenia [207]. Moss et al. 2007 demonstrated 
that, after primary measles immunisation in HIV-infected children, only 88% 
seroconverted compared to 93% of uninfected children. As with adults, the major 
difference was found in the maintenance of protective titres, where the HIV-infected 
children showed rapid decline of immunity compared to uninfected children. The 
same group, in 2010, identified 38 studies in which immune-specific responses were 
analysed in vertically-infected children on ART: in general, responses to childhood 
vaccines administered prior to starting ART were low, and even effective ART did 
not ensure sustained protective immunity, despite initially good antibody responses 
to those vaccines administered on therapy [208]. Reduced antibody avidity after 
immunisation has also been shown in children with HIV infection in the context of 
measles antigen [209].  
 
Children, even without HIV infection, are at high risk of IPD, probably due, at least 
in part, to the delayed maturation of the marginal zone memory compartment, as 
discussed previously. Children with HIV infection, with their disease-associated 
additional deficit of marginal zone memory [202], in addition to deficits in the 
generation of classical immune memory, are thus exceedingly vulnerable. Von 
Gottberg [210] showed a 21-fold greater risk of disease in HIV-infected infants 
compared with healthy controls and also significantly higher rates of pneumococcal 
colonisation [211]. Changes to IgG VH3 repertoire in association with invasive 
pneumococcal disease have also been demonstrated in children which may 
contribute to ineffective humoral responses as discussed previously [212].  
 
As in adults, ART does not appear to entirely restore abnormalities in memory cell 
populations in the paediatric population [199,202] and timing of ART is likely 
relevant in this context.  Promising paediatric data has been presented [213], 
although findings are often inconsistent partly due to difficulties in study 
standardisation. Some studies [199] show some recovery of pre-existing immune 
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memory to tetanus antigen after initiation of ART in addition to protective responses 
to booster vaccines, while others [214] demonstrate an ART-related improvement 
only in the context of revaccination.  
 
Where ART is started early in infection, immune recovery is likely to be greatest. 
Memory B cells have been shown to be preserved in those children started on 
treatment early in the disease course but reduced in those treated later [177]. The 
same study showed relatively preserved responses to common vaccine antigens 
(measured by serum antibody and antigen-specific B cell levels) in those children 
starting ART before the age of one year. Further data from the same group [215] 
suggests reduced humoral and cellular immunity to routine childhood vaccines is 
seen in late ART-treated patients, and that late treatment may also be associated with 
higher frequencies of abnormally activated B cells. 
1.7 HIV infection – does the route of infection matter? 
 
It is clear that HIV infection results in complex and significant abnormalities of the 
B cell compartment. These abnormalities result in impaired ability to generate and 
maintain effective memory responses, with important clinical consequences in terms 
of infection and immunisation. HIV-related B cell dysfunction has been studied 
extensively in adults, infected by the horizontal route, and, to a more limited extent, 
in children, who have acquired their infection by the vertical route.  Almost no data 
exists regarding the HIV-infected young adult population, who represent a mixture 
of vertically and horizontally infected patients. It is not clear whether existing 
findings in adults or children can be extrapolated to this age group, nor whether HIV 
infection affects the B cell compartment differentially in these two subgroups of 
patients, infected by different routes, at different ages, and with different durations of 
infection and history of antiretroviral exposure. An understanding of how vertically 
acquired HIV infection affects immune development has implications for efficacy of 
HIV treatment in adult life and strategies to prevent and treat common infections 
[216].  
Failure to generate effective early immune memory? 
Vertically-acquired HIV infection may result in deleterious effects on long term 
immunity. For these patients, infant immunisations and natural antigen exposure all 
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occur in the context of chronic HIV infection and viraemia. This may lead to long 
term defects in natural and vaccine immunity with significant implications for later 
immune competence.  
 
During childhood, antigen encounter results in establishment of memory B cell 
populations that provide lifelong immunity to most infections. Gradual maturation of 
lymphocyte populations [145,217], antibody responses [218] and increasing capacity 
to mount antibody responses to vaccines [219-221] are seen in early life. This is 
reflected in the two-fold increase of peripheral blood B cells seen in the first five 
months of life, with subsequent decline from the second year until adulthood [217], 
and in the postnatal development of lymph node microarchitecture [222-224]. 
 
Early-life antigen encounter results in the development of the immune repertoire, and 
shapes the specificity and diversity of the subsequent memory response.  The 
concept of ‘original antigenic sin’ refers to the influence of a primary antibody 
response in dictating the specificity and efficacy of subsequent responses. Mouse 
studies [225] showed that the V gene repertoire induced during the initial priming 
stage of a T-dependent antigen-specific immune response was important in 
determining the later efficacy of a secondary response. Thus it is important that in 
the early childhood years when adaptive immunity is developing to many important 
pathogens, the best quality of immunity is generated.  Inability to access and or 
generate antibodies of optimal configuration has been associated with a general 
phenotype of frailty [226].  
 
This early period of life thus appears to offer the optimal opportunity for generating 
appropriate repertoire diversity and is therefore critical for normal immunological 
development. The impact of chronic HIV infection at such an important time may 
have particularly deleterious effects on the generation of optimal diversity of the 
long term immune repertoire. Early deletion of memory clones by HIV via the direct 
action of gp120 protein may result in a permanently damaged antibody repertoire. 
Increased apoptosis, a shift towards exhaustion and cell depletion, and HIV-related 
defects in signalling and trafficking may also contribute to the failure of these 
essential cell populations to develop normally, with consequent long lasting deficits 
in the ability to generate and maintain effective immune memory.   
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What is the potential for immune recovery? 
Whilst acknowledging the issue of ‘original antigenic sin’, it remains unclear 
whether the immaturity of the immune system in early childhood may paradoxically 
provide increased capacity for restoration and regeneration in vertically infected 
patients. Reconstitution of damaged cell pools has been shown in the context of T 
cell recovery in young HIV-infected children, who may compensate for HIV-related 
damage by increased thymic output [227-230], a process which is thought to 
decrease with age (reviewed in [231]). It is not yet clear whether age affects 
reconstitution of the B cell compartment, but it has been shown that even after 
several years of infection, the immune system may remain relatively well preserved 
in asymptomatic vertical HIV infection [232], and encouraging long term outcomes 
have been predicted [233].  
 
Vertically-infected adolescents represent an unknown immunological population 
with an ever improving prognosis with effective treatment. Early immune responses 
form the basis of lifelong immune competence. This population have acquired their 
infection early in life, and, with improving drug therapy, may expect to live many 
years with their HIV infection. Long lasting immune competence is therefore 
important and preserving early immune development may be critical for later 
effective immune function. There is evidence that early treatment may preserve the 
capacity for immune reconstitution in the context of T cells [230] and some 
emerging data suggesting that early initiation of ART  [177] is also needed to 
preserve the B cell compartment. This may have implications for timing of initiation 
of therapy, which is currently based on CD4
+
 counts or AIDS defining illness, and 
for optimisation of immunisation schedules and protocols.  
 
There is an urgent need to develop a greater understanding of the long term 
implications of the early insults posed by HIV infection to the developing humoral 
immune system, in order to better inform use of ART in early childhood and to 
support effective clinical management of the expanding cohort of vertically infected 
young adults. Current treatment protocols vary significantly, with some advocating 
ART only for all children under a year of age [234], and others for all those under 5 
years [235]. There is a paucity of evidence to inform these recommendations and a 
lack of longitudinal studies monitoring the long term impact of HIV infection in 
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childhood. I hypothesise that these vertically infected young adults represent a 
distinct immunological group from their horizontally infected counterparts. This 
thesis investigates the immunological differences between these two HIV-infected 
cohorts, focussing on B cell phenotype and capacity to generate short and long term 
serological memory to pneumococcal immunisation. 
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Chapter 2. Subjects, materials and methods 
2.1 Reagents 
Reagents used are listed in Table 2.1.  
Reagent Source Catalogue number 
Phosphate buffered saline (PBS) Invitrogen Ltd., UK 14190-094 
BD FACS lysing solution BD Biosciences, UK 349202 
BD CellFIX (10x concentrate) BD Biosciences, UK 340181 
Bovine serum albumin (BSA) Sigma-Aldrich, UK A2153 
Saponin  Sigma-Aldrich, UK 8047-15-2 
BD™ CompBead BD Biosciences, UK 552843 
CD19-PeCyTM7, clone SJ25C1 BD Biosciences, UK 341113 
IgM-APC, clone G20-127 BD Biosciences, UK 551062 
IgD-AlexaFluor 700, clone IA6-2 BD Biosciences, UK 561302 
PerCP-Cy5.5 anti-Human CD185 (CXCR5), clone 
TG2/CXCR5 
Insight Biotechnology, 
UK 
335001 
CD95 Mouse Anti-Human mAb (clone DX2), 
Pacific Blue™ Conjugate 
Invitrogen Ltd., UK MHCD9528 
CD38 Mouse Anti-Human mAb (clone HIT2), 
Qdot® 605 Conjugate  
Invitrogen Ltd., UK Q10053 
CD27 Mouse Anti-Human mAb (clone CLB-27/1), 
Qdot® 655 Conjugate 
Invitrogen Ltd., UK Q10066 
CD10 Mouse Anti-Human mAb (clone MEM-78), 
Qdot® 800 Conjugate 
Invitrogen Ltd., UK Q10154 
Human CD21 Affinity Purified Polyclonal Ab, 
Sheep IgG 
R&D Systems, UK AF4909 
Bcl-2 Mouse Anti-Human mAb (clone 100), PE 
Conjugate 
Invitrogen Ltd., UK MHBCL04 
Ki-67 FITC (clone B56); mouse IgG1 BD Biosciences, UK 556026 
Qdot® 705 Antibody Conjugation Kit Invitrogen Ltd., UK Q22061MP 
38 
 
LIVE/DEAD® Fixable Violet Dead Cell Stain Kit, 
for 405 nm excitation 
Invitrogen Ltd., UK L34957 
Multitest 6 colour TBNK reagent BD Biosciences, UK  644611 
Lymphoprep Axis-Shield 
Diagnostics Ltd, UK 
LYS 3773 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, UK D8418-250ML 
QuantumPlex™ carboxylated fluorescent beads; 
COOH 4.4µm and 5.5µm, 10 populations  
Bangs Laboratories 
Inc., UK 
239 
Serotype specific pneumococcal capsular 
polysaccharide  -serotypes 1, 4, 5, 6B, 9V, 14, 18C, 
22F, 23F (PPS) 
ATCC Biologicals, 
UK 
ATCC-161X, 173X, 177X, 
225X, 253X, 197X, 245X, 
213X, 217X 
Serotype specific pneumococcal capsular 
polysaccharide  -serotypes 7F and 19F (PPS) 
Statens Serum Institut, 
UK 
76868, 76958 
Human antibody conjugate: whole IgG Goat Anti-
Human IgG, Fcγ fragment specific (min X Bov, 
Hrs, Ms Sr Prot) 
Jackson 
Immunoresearch, UK 
109-116-098 
R-Phycoerythrin AffiniPure F(ab')2 Frag Dnk 
Anti-Hmn IgM, Fc(5mu) Frag Spec (min X 
Bov,Hrs Sr Prot)  
  
 
Jackson 
Immunoresearch, UK 
709-116-073 
Cell wall polysaccharide (CWPS) Statens Serum Institut, 
UK 
3459 
Table 2.1. Reagents.  
2.2 Study Design 
 
The study investigated cohorts of vertically and horizontally infected young adults, 
and healthy control volunteers. B cell immunophenotyping was performed and 
subjects were immunised with pneumococcal polysaccharide vaccine and their 
serological response monitored over the course of one year. The study design is 
shown in Figure 2.1. HIV-infected individuals were recruited from paediatric and 
adult HIV clinics in London, as described below (Section 2.7). Following informed 
consent, a baseline blood sample was taken and vaccination administered. Serial 
blood samples were then taken at 28 days and 1 year, or at the clinic attendance most 
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closely related to these timepoints, for serum studies. A single “one off” sample was 
taken (at any time) for B cell analysis by flow cytometry.   
 
 
Figure 2.1. Study design.  
 
2.3 Ethical Approval 
 
Ethical approval was obtained from the London Research Ethics Committee (REC 
reference number 10/H0713/1; B cell development and pneumococcal immunity in 
paediatric HIV infection) and informed written consent was obtained from all 
participants. 
2.4 Vaccination Protocol 
  
All participants
1
 were immunised with Pneumovax 23
TM
 (PPV-23) vaccine, 
containing pneumococcal serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 
14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F (Merck & co Inc, UK). The 
vaccination was administered by intramuscular injection to the non-dominant deltoid 
muscle.  
                                                     
1 all participants were immunised except a group of horizontally infected patients with 
history of HIV seroconversion within the previous 2 years. This is further discussed in 
Section 2.7 
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2.5 Clinical Data Collection 
 
Data was gathered from clinical records regarding antiretroviral drug status at each 
blood sampling. At each bleedpoint, a blood sample was also taken concurrently 
with each study sample for clinical laboratory assessment of viral load. Total 
lymphocyte count and CD4
+
 count were analysed by the clinical laboratories at Great 
Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond St, 
London WC1N 3JH. Total lymphocyte count was obtained using a Sysmex XE-5000 
analyser (Sysmex, UK).  CD4
+
 count was analysed by staining 100 µl of whole 
blood with 5 µl of Multitest 6 colour TBNK reagent. After an incubation period of 
10 minutes, the sample was lysed with BD FACS lysing solution and run on a flow 
cytometer (BD FACSCanto II; BD Biosciences, UK). 10,000 lymphocyte events 
were collected; acquisition and analysis was performed using FacsDiva
TM
 software 
(BD Biosciences, UK). Lymphocytes were defined by forward vs. side scatter and 
CD45 vs. side scatter, then gated CD3 vs. CD19. CD3
+
 cells were gated and the 
CD4
+
 vs. CD3
+
 plot was used to define the CD4
+
 population. Absolute CD4
+
 count 
was calculated by multiplication of the CD4
+
 percentage by the total lymphocyte 
count.  The HIV load was determined using the HIV-1 RNA bDNA assay (Bayer 
Diagnostics, UK) by the clinical laboratories at Great Ormond Street Hospital for 
Children NHS Foundation Trust (as above). The lower limit of detection for the 
assay is 50 copies/mL.  
2.6 Sample preparation 
 
Blood for serum studies (5 ml) was taken into plain glass tubes. Serum was separated 
by centrifuging at 3000 rpm for 5 minutes, aliquoted and stored at -80 °C for 
subsequent analysis. Blood for immediate flow cytometric assay (2 ml) was taken 
into an EDTA-coated glass tube. All blood was transported to the receiving centre 
within 12 hours and processed there within 24 hours. Blood for lymphocyte store (20 
ml) was taken into lithium heparinised glass tubes. Lymphocytes were isolated by 
Ficoll density centrifugation and frozen in 10% DMSO for later analysis, outside the 
scope of this thesis.  
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2.7 Subject recruitment  
2.7.1 Subject groups 
HIV-infected populations were recruited from the HIV clinics of Great Ormond 
Street Hospital for Children NHS Foundation Trust (Great Ormond St, London 
WC1N 3JH), Mortimer Market Centre, NHS Camden Provider Services (London 
WC1E 6JB), “56 Dean Street Clinic”, Chelsea and Westminster Hospital NHS 
Foundation Trust (56 Dean St, London W1D 6AQ) and Royal Free London NHS 
Foundation Trust (Pond St, London NW3 2QG). Patients were eligible for inclusion 
if they were aged 12-25 years and had confirmed HIV infection. Patients with 
chronic co-existing non-HIV-related morbidity were excluded, as were those who 
were pregnant or had previously received pneumococcal immunisation with either 
Pneumovax
TM
 (Merck & co Inc, UK) or Prevenar
TM
 (Wyeth  Vaccines, USA).  
Patients were subdivided into those with infection acquired by the horizontal route 
(sexual or blood product transmission with documented evidence of infection more 
than two years previously) (HIV-H; n = 29) and those infected by the vertical route 
(HIV-V; n = 64). All children found to be HIV positive in early childhood, where the 
mother is HIV positive, were regarded as vertically infected although infection may 
have occurred in the perinatal or postnatal period through breast feeding. A further 
cohort of young adults with recently acquired HIV infection (documented first 
positive HIV test within the previous 2 years) (HIV-H-RS; n = 9) was also recruited 
(recent seroconverters); the HIV-RS group did not receive the pneumococcal 
immunisation.  
The control group was composed of healthy adult volunteers, aged 18-25 years 
(CON; n = 51), recruited by approaching students of University College London (by 
email) and staff nurses from Great Ormond Street Hospital NHS Foundation Trust 
(in person). Abbreviations used to denote patient populations are shown in Table 2.2. 
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Patient group Abbreviation 
Healthy control group CON 
Total vertically infected patient group HIV-V 
Horizontally infected patient group (excluding those seroconverted in previous two years) HIV-H 
Horizontally infected patients who have seroconverted in the previous 2 years HIV-H-RS 
HIV viral load positive at the time of sample + (eg: HIV-V+) 
HIV viral load negative at the time of sample - (eg: HIV-V-) 
Vertically infected patient group with early and sustained viral control <10y of age  HIV-V E 
Table 2.2. Patient populations with abbreviations. 
 
  
43 
 
2.7.2 Subject demographics 
 
The demographics of study participants are shown in Table 2.3.  
   HIV infected subjects 
  CON HIV-V HIV-H HIV-H-RS 
N (total)  51 64 29 9 
Age (range) 
(years) 
 22.9 (19.0-
26.1)*‡ 
17.4 (12.4-
25.8)† 
24.6 (20.5-27.1) 
• 
22.6 (20.4-
25.3) 
Female sex (%)  80.4*‡ 
 
56.3 
 
41.4 
 
11.1 
 
Ethnicity (%) White British 56.9*‡ 
 
6.30† 
 
31.0 
 
55.6 
Black 
African 
3.9*‡ 
 
75.0† 
 
31.0 
 
11.1 
Other# 
 
43.4*‡ 
 
14.1† 
 
37.7 
 
33.3 
Unknown 0*‡ 
 
4.70† 
 
0 0 
Table 2.3. Demographics by subject group. 
Data relates to the first sample collected for each patient. Data are median values (range), unless otherwise 
indicated. NA, not applicable. Significance is shown at p < 0.05 for the following comparisons: *CON and 
combined HIV-V and HIV-H; † HIV-V and HIV-H; ‡ CON and HIV-V; •HIV-H and HIV-H-RS (p<0.05); # 
Other: includes : other white background , Asian (Indian, Pakistani, Bangladeshi, Chinese, other Asian), 
Caribbean, Arab, mixed ethnicity (White and Black African, White and Asian, other). 
Vertically infected (HIV-V) patients (median age 17.4 years) were younger than the 
horizontally infected (HIV-H) group (median age 24.6 years). The control group 
(CON), had a median age of 22.9 years. CON subjects were mostly female (80.4%), 
whereas HIV-V and HIV-H patients were more evenly distributed by gender (56.3% 
and 41.4% female, respectively). Three quarters of the HIV-V group were of Black 
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African ethnic origin, whereas the HIV-H group were evenly distributed between 
White British, Black African and other ethnicities.  
Disease parameters in the various subject groups are shown in Table 2.4.  
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  HIV-V HIV-H HIV-H-RS 
Age at initial HIV + diagnosis, whole 
years (range) 
 3 (0-15)† 
 
20 (15-24) 21 (9-25) 
Time since initial HIV + diagnosis, 
whole years (range) 
 12.5 (4-22)† 
 
3 (2-11) • 
 
1 (0-1) 
 
CD4, count, cells/100 µl blood (range)   490 (10-1200) 
 
526 (100-915) 
 
489 (241-
809) 
 
Viral load known to be undetectable 
(n) 
 34 (incl. 1 off 
ART) 
16 (incl. 1 off 
ART) 
 
0 
Detectable viral load/log10 RNA 
copies/ml (n) 
 
50-10,000  
 
18 (incl. 11 off 
ART) 
9 (all off 
ART) 
2 (incl. 1 off 
ART) 
 10,000-
100,000 
9 (incl. 5 off 
ART) 
2 (both off 
ART) 
4 (incl. 3 off 
ART) 
 100,000-
500,000 
2 2 (incl. 1 off 
ART) 
2 (both off 
ART) 
 >500,000 0 0 0 
Viral load unknown (n)  0 0 1 
Individuals known to be on HAART, 
% 
 76.6† 
 
55.2 33.3 
Individuals naïve to HAART, %  7.8† 
 
37.9 55.6 
Table 2.4. Disease parameters by subject group. 
Data relates to the first sample collected for each patient. Data are median values (IQR), unless otherwise 
indicated. HAART: highly active antiretroviral therapy. NA, not applicable. Significance is shown at p < 0.05 for 
the comparisons:* CON and combined HIV-V and HIV-H; † HIV-V and HIV-H, ‡ CON and HIV-V; • HIV-H 
and HIV-H-RS (p<0.05). 
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Median age at diagnosis was 3 years in the HIV-V group, although all patients are 
presumed to have been infected around the time of birth. Median age of diagnosis in 
the HIV-H group was 20 years. There was no difference in CD4
+
 cell count in the 
patient groups, nor in the number with controlled viraemia. Of those HIV-V and 
HIV-H infected patients with detectable viral load (HIV-V
+
 and HIV-H
+
), only 2 
patients in each group had a VL greater than 100,000 copies/ml. A greater proportion 
of HIV-V than HIV-H infected patients were on ART (p = 0.037), and a smaller 
proportion were naïve to therapy (p = 0.003).  
The recent seroconverter group (HIV-H-RS) was similar to the HIV-H group in 
terms of both demographics and disease parameters, although they were slightly 
younger (median age 22.6 years compared to 24.6 years in the HIV-H group) and 
none of the HIV-H-RS group had an undetectable viral load.  
In the HIV-V patient group, viral control in childhood was examined (Figure 2.2).  
 
Figure 2.2. Age of viral control in HIV-V cohort.  
The age at which viral control was achieved is shown. n = 64. 
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Retrospective data was not available for 7 subjects because of recent arrival in the 
UK with incomplete documentation of medical history. 5 of these 7 subjects had 
documented undetectable viral load on arrival to the UK. For those patients for 
whom data was available, the profile was mixed. 12.5% of the cohort had achieved 
viral control by the age of 5 years (HIV-V
E
) of which two thirds maintained it 
thereafter. 33% of the whole group had achieved viral control by the age of 10 years 
of which fewer than half maintained viral control subsequently and indefinitely. 
Approximately 28% of patients had achieved viral control and maintained this by the 
time of this study; 42% had documented evidence of control at a time prior to the 
study but failed to maintain it. 19% had never achieved viral control.  
2.8 Whole blood flow cytometry assay 
2.8.1 Definition of B cell subpopulations by surface marker expression 
 
The markers used to identify CD19
+
 subpopulations by flow cytometry are shown in 
Table 2.5.  
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Marker What is it? Subpopulations  References 
CD19 A protein encoded by the CD19 gene, found on 
the surface of B cells and used to identify this 
cell population. Present from early lineage 
development but not on mature plasma cells. 
Acts as a B cell co-receptor in BCR-antigen 
binding. 
Total CD19+ 
population, 
considered to 
identify B cells 
[236] 
IgM Membrane bound surface IgM.  Transitional cells: 
CD38hi IgMhi 
Plasmablasts: 
CD38hi IgM- 
[237,238] 
 CD38 Associated with intracellular signalling. 
Upregulated during B cell development, in B cell 
activation and in pre-plasma cell (plasmablast) 
differentiation.  
IgD Membrane bound surface IgD.  Naïve cells: IgD
+ 
CD27– 
Marginal zone 
memory (MZM): 
IgD+ CD27+ 
Switched memory 
cells: IgD- CD27+ 
[90,118,119,202,237,238] 
CD27 Tumour necrosis factor receptor. Used to define 
antigen-experienced B cells. Expressed on the 
surface of classical B memory cells and MZM 
cells and generally not on cells of naïve 
phenotype.  
CD21 Also known as complement receptor 2 (CR2). 
Present on mature B cells; binds complement 
fragments enhancing B cell response to 
complement fixed immune complexes and 
antigens. 
CD21 lo cells: 
CD38lo CD21lo 
Mature activated 
cells: CD27+CD21lo 
Exhausted cells: 
CD27-CD21lo 
[237] 
 
[90,193] 
 
[59,193] 
CD10 Also known as the common acute lymphoblastic 
leukaemia antigen (CALLA). Expressed on early 
lymphoid precursors and recent bone marrow 
emigrants with expression reflecting a range of 
transitional states, and lost on maturation to naïve 
mature B cell phenotype. Has enzymatic activity 
over the intracellular concentration of signalling 
peptides.  
Recent bone 
marrow emigrants 
(BME): CD10+ 
[53,90,124,125,193] 
Table 2.5. CD19
+
 subpopulation markers. 
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2.8.2 Development of the twelve colour flow cytometry assay 
 
A twelve colour panel for flow cytometric assay was developed and optimised [239-241]. 
Sourcing of antibody conjugates 
In order to examine all the subpopulations of interest, and to assess expression of 
markers of apoptosis, turnover and proliferation on each, it was necessary to 
incorporate eleven antibody conjugates and one viability dye into the flow cytometry 
panel. In order to achieve maximal resolution of individual markers, it was important 
to minimise spectral overlap of the fluorochromes used. Due to limited commercial 
availability of the required conventional antibody conjugates, Qdot® nanocrystal 
conjugates were used in some cases. These are particles with unique fluorescence 
properties, emitting a light colour dependent on particle size.  Their emission peaks 
are narrow and symmetrical, and they are photostable. In the case of CD21, self-
conjugation of the antibody to a Qdot® was performed, as no commercial reagent 
was available. 
Antibody staining of samples 
Fluorochromes were selected for maximal sensitivity and minimal spectral overlap 
[242]. Appropriate antibody concentration for optimal staining was determined in 
each case by titration studies, as shown in Table 2.6.  
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Antibody Titre in whole blood 
Extracellular staining  
CD19-PeCy7 1:33 
IgM-APC 1:10 
IgD-Alexa Fluor 700 1:50 
CXCR5-PerCPCy5.5 1:33 
CD95-Pacific Blue 1:20 
CD38-QDot®605 1:200 
CD27-QDot®655 1:100 
CD10-QDot®800 1:50 
CD21-QDot®705 1:200 
Intracellular staining  
Ki67-FITC 1:20 
Bcl2-PE 1:33 
Table 2.6. Antibody conjugate concentrations used in flow cytometric assay. 
 
Controls and validation studies  
Use of a viability dye to ensure exclusion of dead cells 
It is important to exclude dead cells from flow cytometric analysis, as dead cells may 
bind antibody non-specifically. A viability dye [243] was incubated with whole 
blood prior to cell staining. Studies over five days were performed to confirm that 
the dye identified dead cells effectively (Figure 2.3). The proportion of live 
lymphocytes was reduced in whole blood after 5 days of storage at room 
temperature, as expected.  
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Figure 2.3. Cell viability studies.  
Blood from a healthy control subject stained with amine viability dye at D0 and D5, showing a reduction in 
viable lymphocytes after 5 days.  
 
Use of compensation controls to reduce the impact of “fluorescence spillover” 
Compensation is the process by which the fluorescence “spillover” originating from 
other fluorochromes is subtracted as a percentage of the fluorescence signal from the 
fluorochrome of interest. Compensation was performed automatically using Flowjo 
software, version 7.6.4 (Treestar Inc.) [244]. Typical compensation plots for a single 
fluorochrome in a healthy control subject are shown in Figure 2.4. These were 
performed for each fluorochrome each time an assay was performed, using 
compensation beads (BD Biosciences, UK). Spectral overlap cannot be eliminated 
entirely, especially with a panel of twelve colours as used here, and does result in a 
reduction in sensitivity resolution, but with careful choice of fluorochromes and 
accurate compensation this can be minimised.  
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Figure 2.4. Compensation plots.   
Plots are shown for a single fluorochrome (Alexa Fluor 700). Compensation was performed automatically using 
Flowjo software (Treestar Inc.). 
 
DISCARD THIS PAGE 
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Monostain controls 
Monostain controls were used to ensure that the positive staining on a single 
fluorochrome was not affected by its use in combination with other stains, ie: that the 
multistain reflects the “true staining pattern” for individual fluorochromes. This was 
tested as part of validation of the assay: the staining of each fluorochrome used 
individually on the CD19
+ 
population was compared to the result seen when the stain 
was used in conjunction with all fluorochromes in the assay. Monostain controls for 
a single fluorochrome are shown in Figure 2.5.  
 
Figure 2.5. Monostain control.  
Monostain controls are shown for a single fluorochrome (APC).  The staining pattern of this fluorochrome on 
CD19+ cells was accurately represented within the multistain, when compared to the monostain.   
 
“Fluorescence minus one” controls 
 “Fluorescence minus one” (FMO) controls were used to determine the threshold of 
positivity for each fluorochrome within the multistain [239,244]. When using a 
single stain, unstained cells may be used for this purpose. However, when multiple 
stains are used, it is important to be sure that the threshold of positivity is not 
affected by spectral overlap from other fluorochromes, thus a “negative control” 
from which to identify positive staining consists of a sample in which the appropriate 
cells are stained with all fluorochromes except the one of interest. In validating the 
assay, FMO controls were performed for all fluorochromes. It was not possible to 
repeat FMO controls for each fluorochrome every time an assay was performed, due 
to limitations of time and cost. In any case, the CD19
+
 subpopulations were, in the 
main, easily identifiable by eye. However, in the case of the CD10
+
 subpopulation, a 
distinct positive population was difficult to identify, so, in this case, an FMO control 
was performed with every assay (Figure 2.6). 
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Figure 2.6. “Fluorescence minus one” control.  
Shown for Qdot 800, the fluorochrome used to identify CD10+ cells. 
 
Positive controls 
For those markers not expressed normally on CD19
+
 cells, such as Ki67, which is 
only minimally expressed on most healthy resting B cells, a positive control was 
required to ensure the fluorochrome-conjugated antibody was effective in detecting a 
positive population, should one be present. To check this, lymphocytes in whole 
blood were induced to proliferate by addition of CpG-Sac. Ki67 staining in these 
proliferating cells was compared to that in resting non-stimulated cells (Figure 2.7) 
to ensure that a population positive for Ki67 was identified.  
 
Figure 2.7. Proliferation control.  
Ki67 staining is shown both on non-proliferating cells and on cells induced to proliferate by addition of CpG-
SAC . Ki67 expression is greater on the proliferating cells. 
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2.8.3 Flow cytometry staining protocol 
 
200 µl of whole blood was washed twice with 2 ml of phosphate buffered saline by 
centrifuging first at 3000 rpm for 10 minutes, followed by careful removal of 
supernatant and a second centrifugation at 1500 rpm for 5 minutes. The resulting cell 
pellet was mixed with 2 µl of a viability dye at room temperature [243], incubated in 
the dark at room temperature for 30 minutes, followed by washing of the cell pellet 
in a solution of 0.5% bovine serum albumin in PBS by centrifugation at 1500 rpm 
for 5 minutes and removal of the cell pellet.  
The washed cell pellet was then mixed well with a mastermix of extracellular 
staining antibodies and incubated for 15 minutes at room temperature in the dark. 
The cells were lysed by adding 2 ml whole blood lysis buffer for 15 minutes, washed 
twice by centrifugation at 1500 rpm for 5 minutes in 1ml 0.5% bovine serum 
albumin in PBS, fixed by addition of 150 µl of cell fixing solution and left in the 
dark for 10 minutes. Intracellular staining was performed by permeabilising cells by 
centrifugation at 1800 rpm for 5 minutes in 2 ml of a permeabilisation buffer (0.5% 
bovine serum albumin in PBS with addition of Saponin to a final concentration of 
0.1%). Supernatant was removed, and cell pellets incubated with a mastermix of 
intracellular antibodies for 30 minutes at 4 °C in the dark, before centrifugation at 
1800 rpm for 5 minutes in 2 ml of 0.5% bovine serum albumin in PBS. The cells 
were fixed once more by addition of 50 µl of cell fixing solution and kept in the dark 
until analysis.  
 
Controls were also prepared. For each batch of samples stained, compensation beads 
were stained for all fluorochromes (including the viability dye), according to 
manufacturer’s instructions. In addition, one unstained sample was also prepared and 
a single “fluorescence minus one” control was prepared, stained with all 
fluorochromes except CD10-QDot®800.  
 
2.8.4 Analysis of flow cytometry data 
 
Analysis was performed immediately using the LSRII (BD Biosciences, UK) with 
FacsDiva
TM
 (BD Biosciences, UK) software. Dead cells, which may bind antibody 
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non-specifically, were excluded by gating on the viability signal, and lymphocytes 
were gated on forward and side scatter. Doublet cells were excluded [245], as these 
“clumped” cells may bind antibody erratically; only those cells passing the laser in 
single file were included, ie those in which height and area are directly proportional 
to one another. CD19
+
 cells were then gated on side scatter vs CD19-PeCy7, and a 
minimum of 10,000 events on this CD19
+ 
gate were collected. Initial gating strategy 
is shown in Figure 2.8. 
 
Figure 2.8. Typical flow cytometry plot showing initial gating.  
Gating used to identify the CD19+ population is shown on a healthy control subject. i) exclusion of dead cells 
using viability dye; ii) gating on lymphocytes on forward and side scatter; iii) exclusion of doublets; iv) gating of 
CD19+ population. 
 
 
Compensation was performed automatically using Flowjo software, version 7.6.4 
(Treestar Inc.), and determined by the compensation controls [244]. Analysis of data 
was also performed using Flowjo software, version 7.6.4.  
 
CD19
+ 
cells
 
were expressed as an absolute number of cells per microlitre of blood, 
which was derived from the total lymphocyte count performed in the clinical 
laboratory at Great Ormond Street Hospital NHS Foundation Trust and the 
percentage of CD19
+
 cells obtained by flow cytometric analysis.  
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The gating strategy used for analysis is shown in Figure 2.9 (healthy control).  
 
CD10
+
 cells were gated on the CD19
+
 population, on a plot of CD10 vs CD21 [124] 
(Figure 2.9, i). This gate position was set using the fluorescence minus one control 
(containing all stains except CD10). CD27
+
CD21
lo
 and CD27
-
CD21
lo
 populations 
were then identified on the CD10
-
 population only, to ensure exclusion of CD10
+
 
cells, which may also be CD27
-
CD21
lo
, (reviewed in [12]) (Figure 2.9, ii). 
CD38
hi
IgM
hi
, CD38
hi
IgM
- 
and CD38
lo
 CD21
lo 
cells were gated on the CD19
+
 
population (Figure 2.9, iii and iv). Finally, IgD
+
CD27
-
, IgD
+
CD27
+
 and IgD
-
CD27
+
 
subpopulations were gated, also on the CD19
+
 population (Figure 2.9, v). 
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Figure 2.9. Subsequent gating to identify CD19
+
 subpopulations.  
Gating is shown on a healthy control subject. i) CD10+ gate set on CD19+ population (based on “fluorescence 
minus one” control) showing immature bone marrow emigrants (CD10+; a); ii) gated on CD19+ CD10- cells, to 
ensure exclusion of recent bone marrow emigrants, showing exhausted (CD27- CD21lo; b); and mature activated 
(CD27+ CD21lo; c) populations; iii) gated on  CD19+ population, showing plasmablasts (CD38hi IgM- ; d) and 
transitional cells (CD38hi IgMhi ; e); iv) gated on CD19+ population, showing CD21lo cells (CD38lo CD21lo ; f); 
v) gated on CD19+ population, showing naïve (IgD+ CD27- ; g), marginal zone memory (IgD+ CD27+ ; h) and 
switched memory cells (IgD- CD27+ ; i). 
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Expression of bcl-2, CXCR5, CD95 and Ki67 was measured in all B cell 
subpopulations. The gating strategy for the markers of cell behaviour in a healthy 
control subject is shown in Figure 2.10.  
 
Figure 2.10. Gating of markers of turnover, apoptosis and trafficking. 
Gating is shown on a healthy control subject. All markers are gated on the total CD19+ population. i) typical 
histogram of bcl-2 expression; expressed as median fluorescence intensity; ii) typical histogram of CXCR5 
expression; expressed as median fluorescence intensity; iii) typical flow cytometry plot of CD95 expression; 
expressed as % positive; iv) typical flow cytometry plot of Ki67 expression; expressed as % positive. 
 
Data regarding B cell subpopulations was analysed by both absolute count and 
percentage; the correlation was generally good thus data regarding CD19
+
 
subpopulations is generally expressed as percentages of the total CD19
+
 count. Bcl-2 
and CXCR5 are expressed as median fluorescence intensity [55,58,59] (MFI), and 
CD95 and Ki67 as percentage of cells positive for expression of the relevant marker 
[53]. Comparison was performed between the CON, HIV-V and HIV-H groups. 
Further analysis was performed after subdivision of the patient groups based on 
whether HIV viraemia was detectable at the time of sampling. Vertically infected 
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patients with a history of permanent viral control early in life, before the age of 10 
years (early viral control; HIV-V
E
) were compared to those with current, but not 
early-life, viraemic control (HIV-V
-
). Some comparisons were also performed 
between the HIV-H and HIV-H-RS groups.  
 
2.8.5 Exclusions 
 
Samples were excluded from analysis where the antibody staining failed (1 assay, all 
studies repeated on a subsequent sample from the same patient), or where it was not 
possible to obtain sufficient CD19
+
 cells to perform analysis (2 HIV-H subjects).  
 
2.9 Serum studies 
 
Quantification of pneumococcal polysaccharide serotype-specific IgM and IgG was 
performed using an established flow based multiplex assay at the Clinical 
Immunology laboratory, Papworth Hospital NHS Trust, Papworth Everard, 
Cambridge CB23 3RE. The assay, shown schematically in Figure 2.11, is based on a 
method described by Lal et al. in 2005 [246], in which individual carboxylated 
fluorescent beads were coated with serotype specific pneumococcal capsular 
polysaccharides (PPS) at appropriately determined concentrations (1:1.4 for 
serotypes 1, 6B, 9V, 14, 18C, 19F, 23F; 1:1.66 for serotypes 4, 5 and 7F) before 
incubation with patient serum and addition of a human antibody conjugate (at a 
concentration of 1:200 for IgG and 1:50 for IgM). A pre-absorption stage with cell 
wall polysaccharide at a concentration of 1: 2500 [247]
 
and serotype 22F at a 
concentration of 1:400 [248] was also performed. Beads were then analysed by flow 
cytometry using a standard flow cytometer (Beckman Coulter FC500) and 
pneumococcal PS binding activity quantified. Data analysis, calibration, validation 
and report generation was performed using in-house developed software (Microsoft 
EXCEL). 
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Figure 2.11. Schematic diagram of the flow-based multiplex assay used for quantification of 
pneumococcal polysaccharide serotype-specific IgM and IgG.  
i) Fluorescent beads (of two sizes and varying fluorescence intensity) coated with polysaccharide, incubated with 
serum and then with human antibody conjugate; ii) identification of beads by size and fluorescence intensity; iii) 
quantification of serotype specific anti-pneumococcal antibodies by fluorescence intensity of human antibody 
conjugate.  
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Pnc IgM and IgG serotype-specific binding activity was assessed for 8 and 10 
serotypes respectively using batched serum taken at baseline, 28 days and 1 year 
after immunisation with PPV, where samples were available.  
Data were expressed in µg/ml. All values below the lower limit of detection were 
assigned a value of 0.01. All values above the upper limit of detection were assigned 
a value of 5 (IgM) and 10 (IgG).   
2.10 Statistics 
 
Data were not normally distributed, even when log transformed, as evaluated by the 
Shapiro-Wilks test, and non-parametric statistical tests were used throughout. Cohort 
data were expressed as median values and interquartile ranges (IQR). Comparisons 
of continuous variables between groups were performed using the Mann Whitney U 
test and comparison of categorical variables was performed using the chi-squared 
test or Fisher’s exact test (depending on sample size). Comparison of related 
variables in the same subject (serology data at various bleedpoints) was performed 
using the Wilcoxon signed rank test. Spearman’s correlation coefficients were used 
to test correlation. Statistical analyses were performed using SPSS software, version 
21 (IBM), and GraphPad Prism software (GraphPad Software Inc.), version 6. The 
Bonferroni correction was considered, in view of multiple comparisons performed, 
but was not applied. This decision was made in view of the fact that raw data is 
displayed, where possible, in the text and figures, with p values quoted. The issue of 
multiple comparisons is considered in the interpretation of the data and is further 
discussed in Chapter 5.  
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Chapter 3. Results: flow cytometric analysis 
3.1 Introduction 
3.1.1 Changes in B cell subpopulations 
 
Evaluation of the peripheral B cell subpopulations in vertically and horizontally 
HIV-infected young adults allows an assessment to be made of a possible differential 
immune effect on humoral immunity of HIV infection in two patient groups, those 
who acquired infection in early life, at the start of the process of development of 
adaptive immunity (HIV-V), and those acquiring infection on the background of an 
established mature immune system (HIV-H). 
Derangement to peripheral B cell subpopulations is well documented in HIV 
infection. Hyperactivation, abnormal turnover, altered trafficking, disrupted 
apoptosis and drive towards terminal differentiation and exhaustion all contribute to 
changes to both the relative proportions and behaviour of various B cell types. It 
must be remembered that these peripheral populations offer only a “snapshot” of the 
overall B cell population, as the majority of B cells reside in the spleen, lymph tissue 
and bone marrow; nonetheless they offer a valuable insight into a range of HIV-
related immune disturbances. The changes in B cell subpopulations may be 
associated with reduced function, altered repertoire and overall deleterious effects on 
humoral immunity, as discussed in Chapter 1. 
Cell surface markers used to identify subpopulations of B cells in this study are 
shown in Table 2.5 (Chapter 2).  
Depletion of mature populations 
An overall depletion of B cells has been reported in HIV infection in adults 
[59,180,249,250] and in children [9,201]. Relatively few studies report on the impact 
on the naïve B cell population, which, in the healthy individual, comprises about 60-
70% of circulating B cells and are required to develop de novo responses to 
previously unencountered antigens. Naïve cells, by definition, have an unmutated 
IgV region sequence [134], simultaneously co-express IgM and IgD [128,134] and 
are usually defined as CD27
-
 (reviewed in [251]). In adults with HIV infection, some 
studies have shown a relative decrease in their frequency in HIV-viraemic 
individuals [90] and reversal of this reduction with HAART [120]. Other studies, 
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however, have shown an increase in CD27
-
 naïve cells in drug naïve patients which 
normalises with viral control [51]; increased CD27
-
 naïve cells has also been 
reported in children with HIV [199] . 
Depletion of existing memory populations is well established in HIV infection. As 
discussed in Chapter 1, B cell memory populations comprise, among others, classical 
memory cells and memory cells believed to represent circulating counterparts of the 
marginal zone memory cells of the spleen (referred to here as marginal zone memory 
cells). Classical memory cells are believed to comprise about 20–30% of all 
peripheral blood B cells in healthy individuals, but in HIV infection, several studies 
have shown a decrease in frequency of these switched memory B cells 
[116,118,120,122,126], although this may only manifest in those patients with low 
CD4
+
 count [119]. This deficit seems not to be restored by ART [55,116,118]; 
indeed, effective ART may in fact reveal an underlying depletion of this cell 
population, not apparent in drug-naïve patients [126].  There is some evidence that 
early ART may prevent memory B cell loss [52,193]. The depletion of the marginal 
zone memory population has also been shown in peripheral blood in adults with HIV 
infection, although it remains controversial whether this depletion is reversed by 
ART [118,119]. This finding in peripheral blood is supported by the demonstration 
of selective atrophy of the marginal zone of the spleen, where MZM B cells are 
generated, early after infection with HIV [252].  
 
In HIV-infected children, the impact on switched memory populations is less clear 
than in adults [177,199,202], with some studies showing no change [202] and others 
showing a decrease in switched memory populations [199]. Children with HIV have 
reduced MZM compared to healthy controls [199], although this depletion may only 
be manifest with viraemic control [202].  One study [177] has shown that in children 
who started ART in the first year of life, memory populations were preserved; this 
was not seen when ART was started after the first year.  
 
Plasmablasts have also been shown to be affected in HIV infection. Plasmablasts are 
short-lived cells on a differentiation route to either short or long lived plasma cells. 
They have high turnover and the capacity to divide and migrate. They are found with 
low frequency (about 1-3%) in adult peripheral blood and have been shown to 
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increase under conditions of immune activation ([253-255], including infectious 
diseases, autoimmune diseases and primary immunodeficiencies [237,256,257]. HIV 
viraemia has been shown to result in increased numbers of terminally differentiated 
B cells and plasmablasts [41,127] in the circulation and increased plasmacytosis in 
the bone marrow [122], probably as a result of the chronic immune-activating effects 
of HIV replication [258]. These cells show increased Ki67 and CD95 expression in 
HIV infection, indicative of increased turnover and susceptibility to apoptosis 
respectively.  
Changes to immature cell populations 
Along with the reduction of effective mature cell populations, there is a tendency in 
HIV infection towards an increase in circulating immature cell populations. This 
may be a compensatory mechanism by which the bone marrow production of 
immature B cells increases to compensate for the depletion of mature peripheral and 
tissue B cells, resulting in an abnormal overspill of immature cell populations into 
the circulation. A population known as transitional cells has been described, 
expressing high levels of both CD38 and IgM. In healthy individuals, their relative 
number decreases significantly during the first year of life and remains low thereafter 
[238]. These cells have been shown to be increased in HIV infection [119] and in 
some types of primary immune deficiency such as CVID, when they are seen to be 
associated with other abnormalities also described in HIV infection, such as 
increased plasmablasts, reduced classical memory cells, and emergence of abnormal 
populations [237]. 
 
A heterogeneous population of immature B cells, recently emigrated from the bone 
marrow to the peripheral circulation, has also been defined by varying degrees of 
CD10 expression [259]. These immature cells are thought to comprise about 2–4% 
of all B cells in healthy individuals [260,261] and to exhibit phenotypic features of 
immature B cells with a lower ability to proliferate and differentiate to antibody-
secreting cells after in vitro stimulation, as compared with naïve mature B cells 
[260,261]. This population of recent bone marrow emigrants has been shown to be 
expanded in conditions with impaired humoral immunity such as systemic lupus 
erythematosus (SLE) [260,261]. In HIV infection, an increase in these immature 
cells was described as early as 1987 [123] in AIDS patients. It has been subsequently 
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shown that these cells may account for as much as 30% of peripheral blood B cells in 
active HIV disease in adults [124], a finding which has been confirmed by many 
others [53,54,126,262], and is seen in children [125,200]. It has also been described 
in other conditions associated with CD4
+
 depletion such as idiopathic CD4
+
 T 
lymphocytopenia [263]. The mechanistic explanation for increased immature B cell 
in the circulation in states of immune activation is unclear and presumably reflects 
altered turnover and survival in the B cell population. A putative mechanism in the 
context of CD4
+
 lymphopenia may involve an association between low CD4
+
 counts 
and increased serum levels of interleukin-7 (IL-7) [264]. IL-7 is known to induce the 
proliferation of human B cell precursors [265] and IL-7 mediated signalling is 
impaired in idiopathic CD4+ lymphocytopenia [266]. It has been shown that high 
serum levels of IL-7 directly correlate with increased frequencies of immature 
transitional B cells in the peripheral blood of HIV-infected individuals, which, in 
turn, correlate with HIV viraemia [124]. 
 
Abnormal expansion of populations 
In addition to the depletion of mature B cell populations, and the possibly 
compensatory increase in immature B cell populations, there is evidence for 
abnormal expansion of some B cell populations in HIV infection, often characterised 
by low CD21 expression, which are seen only at very low frequency in healthy 
individuals [267,268]. These CD21
lo
 B cells have been shown to increase in various 
disease states including rheumatoid arthritis [269], CVID [270,271], SLE [272-274] 
and hepatitis C mixed cryoglobulinaemia [275] and have also been identified in HIV 
infection [45], considered likely to represent two abnormal subpopulations, which 
can be subdivided by CD27 expression (reviewed in [276] and discussed below). 
 
CD27
+
CD21
lo
 expressing cells have been described as mature activated B cells 
[53,90] and comprise less than 5% of circulating B cells in healthy individuals. In 
viraemic HIV-infected individuals they may exceed 25% of the circulating B cell 
compartment [59]. This expansion has been shown in a longitudinal study to be 
reversible with ART [59], consistent with findings that they are found at normal 
level in those HIV-infected patients who are aviraemic. These cells appear to have 
plasmacytoid features, to spontaneously secrete immunoglobulins (perhaps 
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accounting for the hypergammaglobulinaemia seen in HIV infection), to be 
associated with HIV-induced activation, to bear elevated markers of turnover and 
have a high susceptibility to extrinsic apoptosis [41,45,53].  
 
In addition to these CD27
+
 expressing mature activated cells, a further population of 
cells expressing low levels of CD21 exists, which, conversely, do not express CD27. 
These cells have been described as an exhausted subpopulation [59] and were 
initially characterised by identification of a subpopulation of memory B cells in 
human tonsils [268] that expresses the inhibitory receptor Fc-receptor-like 4 
(FCRL4
+
). Following this discovery, increased expression of FCRL4
+
 by peripheral 
blood-derived CD27
-
CD21
lo 
mature B cells in HIV-viraemic (but not HIV-aviraemic 
or HIV-negative) individuals was demonstrated [59].  These cells were found to 
display many features of immunological exhaustion, including altered trafficking, 
and a stunted replication history and an increased expression of inhibitory receptors 
[277], which is a feature of persistent-virus-induced T cell exhaustion [96]. The 
expansion of this B cell population in untreated patients with preserved CD4
+
 counts 
suggests that the emergence of this population may precede the CD4
+ 
decline [278].   
 
3.1.2 Altered expression of markers of apoptosis, turnover and trafficking 
 
HIV infection is associated with various changes in the behaviour of circulating B 
cells in HIV infection, as discussed in Chapter 1. Overall, there is an increased 
tendency towards programmed cell death, with increased turnover in some 
populations, and alterations in the trafficking of B cells between the periphery and 
the lymphoid tissues. These mechanisms may contribute to the altered subpopulation 
distributions discussed above. 
As discussed in Chapter 1, CD95 (Fas) is a death receptor involved in the removal of 
activated immune cells as part of the process of extrinsic apoptosis. In healthy 
individuals, CD95 is weakly expressed on immature B cells and is expressed on 5-
25% of mature peripheral blood B cells, with increasing positivity in more mature 
and activated cells (reviewed in [279]). CD95 expression has been shown to be 
increased on B cells of HIV-infected individuals [41], including immature, naïve, 
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memory and exhausted B cells [51-53,55,116]. Effect of ART on this increase in 
extrinsic apoptosis is controversial: some studies show that it is not reversed by ART 
[54] but others suggest a direct correlation between CD95-mediated apoptosis and 
HIV viraemia and/or reduction with ART [41,51,53,55], though ART-mediated 
improvement may be only partial in the case of memory cells [52,55]. Only a small 
reduction in plasma Fas levels has been described following a year of HAART 
treatment in HIV adults. [116].  
Bcl-2 is an anti-apoptotic protein which is, in healthy individuals, expressed 
differentially at different stages of B cell development; it is highly expressed in pro-
B cells and mature B cells but downregulated at the pre-B stage of development. In 
HIV infection, bcl-2 protein expression has been shown to be reduced on naïve and 
immature cells (in HAART-naïve but not in treated patients) and correlated 
negatively with degree of activation as shown by CD38 expression [51,52]. No 
difference in bcl-2 expression was seen in CD27
+
 memory cells between treatment-
naïve patients, those on HAART and healthy controls, all of whom express high 
levels of bcl-2 suggesting resistance to apoptosis [55]. 
Cell turnover has been shown to be increased in HIV infection [49,93]. The 
expression of Ki67, a nuclear protein expressed in proliferating cells has been 
shown, ex vivo, to be a useful marker for cell turnover [93] and is increased in those 
cells demonstrating high levels of activation and differentiation, mature activated 
cells and plasmablasts [41,53], probably reflecting a drive towards terminal 
differentiation and exhaustion. 
Abnormal B cell trafficking has been extensively discussed in Chapter 1. CXCR5 is 
a chemokine receptor important in recruiting B cells to lymph nodes to enable 
development of the classical memory response. It is expressed by all mature B cells 
[280], particularly circulating naïve cells [253,281], maintained on memory B cells 
[114,282] and lost on plasma cells which are not thought to re-circulate through 
lymphoid tissue [253]. Abnormal reduction of CXCR5 expression has been 
demonstrated on several B cell subpopulations in HIV infection, including naïve B 
cells [51,58], mature, memory and pre-plasma cells [58] and exhausted cells [59] 
suggesting that HIV infection alters B cell trafficking. This reduction in CXCR5 
expression appears to be due to internalisation of the CXCR5 receptor induced by 
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upregulation of the gene encoding its ligand, CXCL13 [58]. It has been suggested 
that this may, in vivo, reflect abnormally high CXCL13 expression, particularly by 
immature dendritic cells, leading to an increase in B cell migration to areas of 
inflammation and immune activation, which may result in impairment of normal 
migration towards the germinal centre. 
Some of the changes to B cell subpopulations and behavioural markers associated 
with HIV infection are reversible with viral control [41,59,90,193], discussed fully in 
Chapter 1 and shown in Table 1.4. However, changes to memory cell populations 
may not be fully reversed even with effective antiretroviral therapy 
[90,116,118,119], and there is some evidence that viral control early in life may be 
important in those individuals infected from childhood, in preventing damage. The 
impact of growing up with HIV with and without viral control on B cell lineage and 
behaviour is not known, and although existing studies have examined the impact of 
HIV on the B cell compartment in both adults (presumably mostly horizontally 
infected) and children (presumably infected by the vertical route), no direct 
comparison has been performed of these two distinct groups. This study compares 
the two groups both with healthy controls and with one another, in order to examine 
whether these two groups suffer a different impact of HIV infection in terms of their 
B cell phenotype and behaviour. 
 
3.2 Methods 
 
The methods are fully described in Chapter 2, section 2.8. 
In brief, a single 2 ml blood sample was taken from each study participant and 
analysed by flow cytometry. A twelve colour flow cytometry panel was designed to 
evaluate naïve and memory (marginal zone and switched) cells, plasmablasts, 
immature and CD21
lo
 B cell populations. Markers of apoptosis, turnover, and B cell 
trafficking were also assessed. Whole blood was stained with appropriate 
concentrations of fluorochrome-conjugated antibodies. Appropriate controls were 
included (see Appendix). Data was analysed using the LSRII (BD Biosciences, UK) 
with FacsDiva
TM
 (BD Biosciences, UK) software. Compensation was performed 
automatically and analysis of data was performed using Flowjo software, version 
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7.6.4 (Treestar Inc.). Data was also collected regarding viral load, CD4
+
 count and 
total lymphocyte count from the same blood sample.  
 
Data for B cell subpopulations is shown as a median percentage of the total 
population of B cells, as discussed in Chapter 2. The changes in B cell 
subpopulations were also measured in terms of absolute cell count; these were 
broadly similar to the changes in percentage.  
Expression of bcl-2, CXCR5, CD95 and Ki67 were measured in all B cell 
subpopulations. Patterns of change were similar among all populations, and were 
reflected, overall, by the patterns of change found on the total CD19
+
 population; 
data is therefore reported for the total CD19
+
 population only. Bcl-2 and CXCR5 are 
expressed as median fluorescence intensity (MFI), and CD95 and Ki67 as percentage 
of cells positive for expression of the relevant marker, as discussed in Chapter 2.  
 
3.3 Results 
 
To evaluate whether the effect of HIV on B cell populations is similar in young 
adults who have grown up with HIV infection compared with those who acquired 
infection in adult life, flow cytometric analysis was used to examine peripheral B 
cell subpopulations in each of three groups. The subject groups and samples included 
in the flow cytometric analysis are shown in Table 3.1.  
  HIV infected subjects 
 CON HIV-V HIV-H HIV-H-RS 
N 47 53 27  9 
Viral load undetectable at time of sample (n)  33 17 3 
Viral load detectable at time of sample (n)  20 9 4 
Viral load unknown (n)   0 1 2 
Table 3.1. Samples included in flow cytometric analysis. 
3.3.1 Overview 
 
The total B cell count was similar between healthy control and vertically infected 
patients and HIV-H had lower counts than both the CON and HIV-V populations; 
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when analysed by VL control, in horizontal infection, there was a reduction in 
absolute B cell count where viral load was not controlled (p = 0.009; Figure 3.1).  
 
Figure 3.1. CD19
+
 absolute cell count in all groups. 
The median is indicated. Red indicates current detectable VL (HIV-V+ and HIV-H+); blue indicates maintained 
viral control <10y of age in the vertically infected group (HIV-VE); grey indicates VL status unknown. * p ≤ 
0.05. 
 
An example of flow cytometry plots from a typical control and HIV-infected patient is 
shown in Figure 3.2.  
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Figure 3.2. Typical flow cytometry plots showing CD19
+
 subpopulations in a healthy control 
(left) and HIV-infected subject (right).  
i) BME (CD10+); ii) mature activated (CD27+ CD21lo) and exhausted (CD27- CD21lo) B cells; iii) plasmablasts 
(CD38hi IgM-) and transitional cells (CD38hi IgMhi); iv) CD21lo B cells (CD38lo CD21lo); v) naïve (IgD+ CD27-), 
marginal zone memory (IgD+ CD27+), and switched memory (IgD- CD27+) B cells.  
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Figure 3.3. Overview of changes in CD19
+ 
subpopulations in all groups. 
Median values are shown for CON (n = 47), HIV-V (n = 53), HIV-H (n = 27). 
 
Relative proportions of different B cell subpopulations were broadly similar in the 
three cohorts (Figure 3.3). The B cell compartment was dominated (about 2/3) by 
naïve B cells, with a smaller proportion of memory cells, including switched and 
marginal zone memory cells. Relatively low proportions of immature B cells, CD21
lo
 
B cells and plasmablasts were seen in all groups.  
There was a general trend in HIV infected patients (both HIV-V and HIV-H) in the 
peripheral blood towards an increase in immature, and CD21
lo
 cell populations. 
Whilst many of the changes in B cell populations were similar in both disease 
groups, some distinct patterns were seen; these are discussed below. 
 The pattern of expression of the dynamic markers on individual B cell 
subpopulations showed considerable variation by cell phenotype (Figure 3.4). This 
pattern was similar between controls and both patient groups (data not shown) 
although intensity of expression was altered in disease. Bcl-2 was expressed on all 
subpopulations, particularly on MZM and switched memory cells; CD95 was also 
universally expressed, with highest expression on activated populations. Ki67 was 
expressed at low levels on all cell populations, with greatest expression on 
plasmablasts and mature activated cells. CXCR5 was expressed more intensely on 
recent BME and naïve B cells.  
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Figure 3.4. Expression of markers of apoptosis, turnover and trafficking across CD19
+ 
subpopulations. 
All markers are gated on the total CD19+ population. Median values and IQR are shown in healthy control 
subjects. n = 47. 
 
In HIV-infected patients, both HIV-V and HIV-H, expression of markers of 
apoptosis, trafficking and turnover was abnormal compared to that seen in healthy 
controls. An example of flow cytometry plots from both a healthy subject and an 
HIV-infected subject is shown in Figure 3.5. 
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Figure 3.5. Typical flow cytometry histograms and dot plots of markers of apoptosis, 
turnover and trafficking in a healthy control (left) and HIV-infected subject (right). 
 i) Bcl-2 and ii) CXCR5; expressed as median fluorescence intensity; iii) CD95 and iv) Ki67; expressed as % 
positive. All markers are gated on the total CD19+ population. 
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3.3.2 Changes in B cell subpopulation distribution in vertically acquired HIV infection 
compared to healthy controls 
 
A number of changes in circulating B cell populations were seen in patients with 
vertically acquired infection compared with the control group (Figure 3.6 a-i). In the 
vertically infected cohort, the B cell population was more dominated by cells of 
naïve phenotype, including naïve cells (p = 0.007), CD38
hi
IgM
hi
 transitional cells (p 
< 0.001) and immature BME (p = 0.006). CD21
lo
 cells (p < 0.001) and exhausted 
cells (p < 0.001) were also increased. These changes were not affected by control of 
viral load; however, the proportion of mature activated cells was increased only in 
those patients who remained viraemic (p < 0.001). The increase in naïve populations 
was balanced by a reduction in MZM (p = 0.030) and switched memory (p < 0.001) 
populations. When analysed by viral control, the increase in naïve B cells and 
reduction in MZM was only seen in those patients with viral control (p = 0.003 and p 
= 0.011 respectively) and was not seen in patients with viraemia. Plasmablast 
proportion was reduced in HIV-V (p < 0.001) compared to controls; this was not 
affected by viral control.  
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Figure 3.6 a-c. B cell subpopulations in all groups. 
The percentage of total CD19+ population with median is shown. Red indicates current detectable VL (HIV-V+ 
and HIV-H+); blue indicates maintained viral control <10y of age in the vertically infected group (HIV-VE); grey 
indicates VL status unknown. * p ≤ 0.05. 
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Figure 3.6 d-f. B cell subpopulations in all groups. 
The percentage of total CD19+ population with median is shown. Red indicates current detectable VL (HIV-V+ 
and HIV-H+); blue indicates maintained viral control <10y of age in the vertically infected group (HIV-VE); grey 
indicates VL status unknown. * p ≤ 0.05. 
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Figure 3.6 g-i. B cell subpopulations in all groups. 
The percentage of total CD19+ population with median is shown. Red indicates current detectable VL (HIV-V+ 
and HIV-H+); blue indicates maintained viral control <10y of age in the vertically infected group (HIV-VE); grey 
indicates VL status unknown. * p ≤ 0.05. 
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3.3.3. Comparison of vertically and horizontally HIV-infected patients 
 
In the HIV-H cohort compared to healthy controls, as with HIV-V, an increase was 
seen in transitional cells (p < 0.001), immature BME (p < 0.001), exhausted (p = 
0.004) and mature activated cells (p < 0.001); these changes were seen regardless of 
viral control. A decrease in plasmablasts was seen only in the aviraemic horizontally 
infected patients (p = 0.034). Differences were also seen in B cell subpopulations 
between the two HIV cohorts. Immature BME and mature activated cells were 
increased in HIV-H compared to HIV-V (p = 0.018 for both populations).  Naïve cell 
proportions were increased in HIV-V compared to HIV-H (p = 0.004) and MZM and 
switched memory populations reduced (p = 0.002 and 0.017 respectively).  
3.3.4 Changes in expression of markers of apoptosis, turnover and trafficking 
 
There were marked changes in expression of these markers in both HIV cohorts 
relative to controls and these changes were generally similar between horizontally 
and vertically infected individuals and were influenced by viraemia in some cases. 
Expression of bcl-2 was similar in all groups, although a decrease in expression 
compared to controls was apparent in the HIV-V
+
 group (p = 0.001) (Figure 3.7a). 
Expression of CXCR5 was reduced in the viraemic subgroup of each cohort (p < 
0.001 for HIV-V
+
 and 0.007 for HIV-H
+
) (Figure 3.7b). CD95 was expressed at 
greater levels in both disease groups compared to controls (p = 0.001 for both 
groups), and was manifest regardless of viral status in HIV-V (p = 0.001), but 
limited to the viraemic subgroup of the HIV-H cohort (p = 0.000) (Figure 3.7c). 
Ki67 expression was increased in viraemic HIV-H (p = 0.005) and in the HIV-V 
cohort overall (p = 0.035) (Figure 3.7d). 
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Figure 3.7 a-b. Expression of markers of apoptosis and trafficking on CD19
+
 cells, shown in 
all groups. 
a) bcl-2 and b) CXCR5 expression (MFI) with median is shown. All markers are gated on the total CD19+ 
population. Red indicates current detectable VL (HIV-V+ and HIV-H+); blue indicates maintained viral 
control <10y of age in the vertically infected group (HIV-VE); grey indicates VL status unknown. * p ≤ 
0.05.  
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Figure 3.7 c-d. Expression of markers of apoptosis and turnover on CD19
+ 
cells, shown in 
all groups. 
c) CD95 and d) Ki67 (% positive) expression with median is shown. All markers are gated on the total CD19+ 
population. Red indicates current detectable VL (HIV-V+ and HIV-H+); blue indicates maintained viral control 
<10y of age in the vertically infected group (HIV-VE); grey indicates VL status unknown. * p ≤ 0.05.  
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3.3.5 Effect of CD4
+ 
count and viral load on B cell subpopulations  
 
There was no strong association between absolute CD4
+
 count and the B cell 
populations or behavioural markers analysed. Direct comparison of aviraemic and 
viraemic (at the time of sampling) patient subgroups, however, influenced population 
phenotypes and some behavioural markers, particularly in the vertically infected 
cohort. In the vertically infected cohort, there was an increase in transitional (p = 
0.003), mature activated (p = 0.019) and exhausted (p = 0.007) cells in HIV-V
+
 
compared to HIV-V
-
 subjects. Bcl-2 and CXCR5 expression was also lower and 
CD95 higher in HIV-V
+
 compared to HIV-V
-
 subjects.  
Effect of early life viral control 
In the HIV-V group, patients with a history of maintained viral load control achieved 
before the age of 10 years (HIV-V
E
) were compared to those HIV-V patients with 
current (but not early-life) viral control (HIV-V
-
) (Figures 3.6 a-i). There was a 
reduction in HIV-V
E
 compared to HIV-V
-
 in the proportion of transitional cells (p = 
0.009), CD21lo cells (p < 0.001), mature activated cells (p = 0.044) and exhausted 
cells (p = 0.011), and an increase in plasmablasts. There was also a trend towards 
increased total CD19
+
 count, MZM, and switched memory populations and to a 
decrease in BME and naïve B cells in HIV-V
E
, compared with HIV-V
-
. Patients with 
early life viral control showed decrease in CD95 expression (Figure 3.7c) and 
increase in Ki67 expression (Figure 3.7d) compared with those with current but not 
early life control (p = 0.048 and 0.03 respectively) and a trend towards increased bcl-
2 (Figure 3.7a) and CXCR5 expression (Figure 3.7b) in HIV-V
E
 compared to HIV-
V
- 
. 
3.3.6 Effect of recent HIV seroconversion in horizontally infected patients 
 
To evaluate whether duration of infection influenced the alterations in B cell profile 
seen, recent seroconverters (HIV-H-RS) were compared with patients with longer 
duration of infection of horizontally acquired infection (HIV-H). There was no 
difference between HIV-H and HIV-H-RS in total CD19
+
 count (Figure 3.8), nor in 
B cell subpopulations (Figure 3.9 and 3.10).  
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Figure 3.8. CD19
+
 absolute count in HIV-H and HIV-H-RS groups.  
The median is indicated. The median and IQR for CON is shown for reference. Red indicates current detectable 
VL (HIV-H+ and HIV-H-RS+; grey indicates VL status unknown. 
 
Figure 3.9: Overview of changes in CD19
+ 
subpopulations in HIV-H and HIV-H-RS groups. 
Median values are shown for HIV-H (n = 27) and HIV-H-RS (n = 9).  
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Figure 3.10: Changes in CD19
+ 
subpopulations shown in HIV-H and HIV-H-RS groups. 
Percentage of total CD19+ population with median is shown. The median and IQR for CON is shown for 
reference. Red indicates current detectable VL (HIV-H+ and HIV-H-RS+); grey indicates VL status unknown.  
 
HIV-H-RS patients were found to have reduced CXCR5 expression on CD19
+
 cells, 
in comparison to HIV-H (p = 0.001) (Figure 3.11b).   
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Figure 3.11: Changes in expression of markers of apoptosis, turnover and trafficking on 
CD19
+
 cells, shown in HIV-H and HIV-H-RS groups. 
a) bcl-2 and b) CXCR5 (MFI), c) CD95 and d) Ki67 (% positive) expression with median are shown. All 
markers are gated on the total CD19+ population. The median and IQR for CON is shown for reference. Red 
indicates current detectable VL (HIV-H+ and HIV-H-RS+); grey indicates VL status unknown. * p ≤ 0.05.  
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3.4 Discussion 
 
I evaluated the impact of HIV infection on circulating B cell subpopulations in 
vertically and horizontally infected young adults, and healthy controls. The data 
presented here demonstrate that the B cell compartment is profoundly altered in 
vertically infected HIV patients by early adulthood, compared to uninfected young 
adults. There is evidence in this vertically infected cohort of ongoing immune 
exhaustion, altered trafficking and increased susceptibility to apoptosis, related to 
HIV viraemia and similar to that seen in horizontally infected patients. Depletion of 
memory populations, however, was demonstrated in vertically infected patients but 
not seen in horizontally infected young adults.  
Increased immature, exhausted and abnormally activated B cells 
[41,53,54,59,119,123-126], with increased apoptosis [41,51-55,116], proliferation 
[41,53] and abnormal B cell trafficking [58,59] are well described in the B cell 
compartment in HIV infection. I did not, however, show a decrease in bcl-2 
expression in horizontally infected patients, even in those with detectable HIV 
viraemia, and a decrease was only demonstrated in the viraemic subgroup of the 
vertically infected cohort. This is in contrast to other studies [51,53,55], and may be 
due to the younger age group of our cohorts compared to those examined in other 
studies, with consequent likely shorter duration of infection in our horizontally 
infected cohort at least. Interestingly, plasmablasts are shown here to decrease in 
both patient groups compared to healthy controls. This is the first published data 
regarding plasmablast populations in vertically infected individuals, but is 
contradictory to other studies in adults [41,258], which have shown an increase in 
plasmablast proportion. This may be partially explained by the difference in age (and 
possibly duration of HIV infection and history of exposure to ART) in our patient 
cohort; it should also be remembered that sample sizes in this study were small. 
In this study, it is noteworthy that the increase in immature and abnormally activated 
B cells was greater in the horizontally infected cohort compared to the vertically 
infected patients, despite a similar degree of viral control between the two groups. 
Groups were not matched for ethnicity; however limited existing data suggests that 
the impact of ethnicity on B cell subpopulations is minimal [283]. Recency of 
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infection in the horizontal group is also unlikely to be relevant, because there was no 
difference between the horizontally infected cohort and a separate cohort of 
horizontally infected patients who had acquired their HIV infection within the 
previous 2 years (although this data must be interpreted with caution as the sample 
size of recently infected patients was small and not powered for this comparison). 
Indeed, duration of infection is longer in the vertically infected group, and might be 
expected to lead to greater changes than those seen in the horizontally infected 
cohort, although no studies have directly examined this. An alternative explanation is 
that acquisition of infection at a young age may be associated with a degree of 
resilience against these dynamic immunological changes of hyperactivation and 
exhaustion seen in those infected in adulthood. Selection bias may also play a role: 
those patients who have survived into adulthood despite vertical HIV transmission 
may represent a distinct group of vertically infected patients who are 
immunologically more robust and/or tolerant of their virus.  
It is also possible that these changes are less obvious in vertically infected patients 
because of the depletion of some cell lineages, such as memory populations, in 
which the changes of hyperactivation and exhaustion might have been demonstrated. 
Changes in memory populations were demonstrated in the vertically infected cohort, 
who showed increased naïve B cell proportion, and reduction of MZM and switched 
memory populations, but not in the horizontally infected cohort.  
In contrast to our findings, depletion of memory populations in horizontally infected 
adults [55,116,118-122] has been shown by others. It is possible that the tendency, in 
recent years, to treat HIV-infected individuals at higher CD4
+
 thresholds has resulted 
in preservation of memory B cell populations in the horizontally infected adults in 
our study, compared to those included in studies performed some years ago. Our 
cohort was considerably younger than those reported elsewhere; this may imply a 
shorter duration of infection, compared to the older patients included in most 
published studies. If duration of infection is indeed important, this may also explain 
the changes to memory populations shown in the vertically infected cohort, who 
have, by nature of their route of infection, endured lifelong HIV infection. Splenic 
histological analysis has indicated that disruption to splenic architecture, including to 
germinal centres and presumably including the marginal zone, occurs late in HIV 
infection [252]. It may be that our vertically infected cohort have progressed to a 
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stage of infection where maintenance and generation of memory cells, of both 
marginal zone and switched type, is compromised, whereas the horizontally infected 
cohort may not yet have sustained a sufficiently long duration of HIV infection to 
develop these changes. This may be consistent with other studies showing that 
treatment early in infection may be of benefit in adults [52,193], although this 
remains controversial [284].  
The increase in naïve B cell proportion is also reflected in the absolute naïve B cell 
count.  This may result from increased production of this cell population, perhaps to 
compensate for depletion of memory populations in these vertically infected patients. 
It may also result from a reduced progression of naïve B cells already in the 
circulation towards generation of memory cells, as discussed above, resulting in 
accumulation. The increase may be restricted to the vertically infected cohort 
because of the depletion of memory cell populations sustained by this group. It is 
also possible, however, that this cohort has a greater capacity for immune restoration 
via repopulation of the naïve cell pool, perhaps because of their long term exposure 
to HIV infection.  
 
The increase in exhausted, activated and immature B cell subpopulations, and 
disturbances of B cell behaviour, were most manifest in the viraemic subgroups of 
each patient cohort, although most of the changes in subpopulations were still 
evident, albeit to a lesser extent, even in aviraemic patients, compared to healthy 
controls. This may suggest partial reversibility of the subpopulation disturbances 
with effective ART, although this is not a longitudinal study so this cannot be 
confirmed. The apparent reduction in subpopulation derangement with viral control 
is broadly consistent with reported data showing that changes to some B cell 
subpopulations can often be reversed with effective ART [90].  Interestingly, in the 
case of the naïve and MZM populations, and in contrast to most other populations 
studied, these changes were in fact most evident when viral load was controlled. This 
is consistent with data in younger children [202] and has also been shown in the 
context of memory populations in adult HIV subjects [126]. This may, perhaps, be 
explained by a role of ongoing viraemia in maintaining turnover of the MZM 
population, ensuring ongoing replacement of the population as depletion occurs. 
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Depletion, therefore, may only become obvious once viraemia is controlled, and a 
new steady state achieved. This may also explain the restriction of the increase in 
naïve cells to those vertically infected patients with viral control, which may be 
partially driven itself by the depletion in the MZM population. Although the 
depletion of switched memory cells is apparent in both viraemic and aviraemic 
subgroups, there is a trend towards greater depletion in aviraemic individuals, 
suggesting that a similar mechanism may also underlie the dynamics of the depletion 
of this population.   
Although viral control in later life does not seem to entirely reverse the HIV-
mediated derangement to B cell subpopulations, the B cell compartment seemed less 
affected in young HIV-V adults with early and sustained viral control, suggesting 
that in children, derangement in B cell development may be either avoidable and/or 
reversible with ART. This is consistent with published work showing that viral 
control in the first year of life may be important in preserving B cell memory 
populations and responses in children [177]. It is possible that the damage to 
memory populations seen in vertically infected young adults may result from HIV 
viraemia during the early period of critical immune development in childhood.  
Interpretation of this data is subject to some limitations. It is important to remember 
that the subpopulations detectable in the peripheral blood are dynamic and may not 
accurately reflect those present in lymphoid tissue and bone marrow. Furthermore, 
the phenotypic definitions of cell types are complex and themselves subject to 
controversy. For example, CD27 expression has traditionally been considered the 
marker of memory B cells [134], with CD27
- 
cells assumed to be naïve. However, 
CD27
-
 memory cells have been proposed to exist in peripheral blood in both healthy 
patients and in disease states albeit in low numbers [285,286]. Theoretically, this 
may mean that CD27
- 
memory cell losses are incorrectly attributed to the naïve 
compartment.  Similarly, definition of memory cells by CD27 expression is 
complex: CD27 is also a marker both of B cell activation and terminal differentiation 
[282], both of which are manifest in HIV infection; thus CD27 expression may not 
represent true immune memory alone [287]. Other cell subpopulations are defined by 
varying markers in different studies, making direct comparison with existing 
literature challenging. Sample sizes in this study were small, of the horizontally 
infected cohort in particular, and further reduced by subdivision of groups by viral 
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control, meaning that interpretation must be made with caution, particularly as the 
variation of B cell subpopulations even in healthy individuals may be considerable. 
That said, other published studies report findings from patient cohorts of similar 
sizes, so this alone may not explain discrepancies from other published data. 
These limitations notwithstanding, our study shows that vertically infected young 
adults show a lesser degree of dynamic immunological changes affecting their B cell 
compartment, but more significant damage to memory compartments, most manifest 
when viral load is controlled, in comparison to their horizontally infected 
counterparts. 
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Chapter 4. Results: natural and vaccine induced response to 
pneumococcal polysaccharide  
4.1 Introduction 
4.1.1 Pneumococcal immunity in HIV infection 
 
Pneumococcal immunity is known to be impaired in HIV infection. Rates of invasive 
disease are significantly elevated in both HIV-infected adults and children in the 
absence of ART [159,165,288-291], and it remains unclear whether the incidence of 
invasive pneumococcal disease has declined since the introduction of HAART.  
4.1.2 Pneumococcal vaccine responses in HIV infection 
 
In addition to impaired responses to natural infection, reduced response to 
immunisation with pneumococcal vaccines is also seen in individuals with HIV 
infection. There are two types of pneumococcal vaccine currently in use, the 
pneumococcal polysaccharide vaccine, Pneumovax™ (PPV) and the conjugate 
vaccine, Prevenar™ (PCV), which generate different kinds of immune response 
depending on the age of the individual and previous exposure. The response to 
immunisation with both vaccines is influenced by pre-existing natural immunity.  
Many patients have been colonised with a number of pneumococcal serotypes [154] 
such that immunisation may induce a mixture of primary responses in those 
individuals who have never been colonised and secondary immune responses in 
individuals who have been affected by prior colonisation [292].  
Pneumococcal polysaccharide vaccine (PPV) 
Nearly 100 different pneumococcal capsular serotypes exist and in general, antibody 
produced against one serotype is not protective against another. Pneumovax™ is a 
23-valent pneumococcal polysaccharide vaccine containing a mixture of capsular 
polysaccharides from the most common disease-causing serotypes and has been 
shown to be effective in reducing the incidence of IPD, though less so in terms of 
protection against pneumonia [293]. As a pure polysaccharide, it acts in a T cell-
independent manner, by cross-linking the B cell receptor and directly stimulating 
differentiation to plasma cells which secrete both IgM and IgG antibodies. This T 
cell-independent antibody response is characterised by delayed class switching, poor 
affinity maturation [143,294] and inability to generate an effective long lived 
memory response [152,295] in a naive individual. In addition, Pneumovax™ is 
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ineffective in children under 2 years of age [296], in whom T cell-independent 
responses are immature. Natural immunity may be boosted by vaccination or 
revaccination by this mechanism; however, there are concerns in adults that repeated 
use of PPV may in fact lead to subsequent attenuation of responses to Pnc exposure, 
a phenomenon known as immune hyporesponsiveness [295,297], which may suggest 
that the potential to boost memory responses through PPV may be limited. The 
mechanism behind this hyporesponsiveness remains unclear and has recently been 
attributed to depletion of long lived plasma cells [298].  
 
Immunisation with a single dose of PPV is recommended for HIV-infected adults 
who have a CD4
+ 
cell count greater than 200 cells/ml, in order to prevent severe 
pneumococcal infections [299]. However, the antibody response is impaired in the 
HIV-infected population. This is considered in part to be due to early damage to the 
marginal zone of the spleen [119] which is known to be important in supporting the 
development of an effective response to pneumococcal vaccines. Poor responses to 
PPV in HIV infection are well documented [172,181,183,300,301], with reduced 
duration and magnitude of serum IgG response compared to healthy individuals 
[80,302,303] and the risk for S. pneumoniae infections remains high among these 
individuals despite immunisation with PPV [160,164,304]. Kroon and colleagues 
[181] monitored specific anti-pneumococcal antibodies for 5 years after PPV 
administration, and showed a significantly lower mean antibody concentration in 
HIV patients with low CD4
+ 
counts for 3 of the 8 serotypes examined. Although the 
rate of decline of antibody concentration showed no difference compared to healthy 
controls, within three years of vaccination, most HIV-infected individuals had 
antibody concentrations below 1.0 µg/mL, considered in this study to be the level 
required for clinical protection. French et al. [305] showed that Pneumovax™ had 
some degree of immunogenicity in HIV-infected Ugandan adults, but the response 
was suboptimal, consistent with the efficacy findings of a systematic review [174] in 
which 11 of the 15 observational studies found various, but limited, degrees of 
disease protection after PPV administration.  A further study by a group in Uganda 
[306] confirmed poor efficacy of PPV in HIV infection, and that its use was 
inexplicably associated with more pneumococcal disease events. Watera and 
colleagues [307] conducted a prolonged follow-up of these patients, and confirmed a 
persistent excess of all-cause pneumonia in vaccine recipients but, nonetheless, an 
94 
 
unexplained survival advantage favouring vaccination. Although use of ART 
improves the response to pneumococcal vaccination [308], post-vaccination antibody 
levels are still lower among ART-treated individuals compared with HIV-uninfected 
people [185]. It appears, therefore, that the effectiveness of PPV in the HIV-infected 
population is controversial, limited and dependent upon the degree of virus-related 
immune deficiency [80,173].  
 
Protein–polysaccharide conjugate vaccines (PCV) 
Following the success of the polysaccharide—protein conjugate vaccines in inducing 
protective immunity in infants to the encapsulated bacteria Haemophilus influenzae 
type B in the early 1990s, polyvalent pneumococcal conjugate vaccines were 
developed. The first vaccine, a 7 valent vaccine; Prevenar-7™, was introduced into 
the infant immunisation schedule in 2006 and recently superseded by a 13-valent 
vaccine, Prevenar-13™ in 2010, to address the issue of serotype replacement 
disease.  
The PCV elicits a T cell-dependent response [309], achieved by chemical 
conjugation of the polysaccharide to a protein carrier such as tetanus toxoid, 
diphtheria toxoid or cross-reactive material 197 (CRM197; a mutated diphtheria 
toxoid). This results in processing of the protein carrier by polysaccharide-specific B 
cells and MHC class II-mediated presentation of the constituent peptides to specific 
T cells, generating antigen-specific T cell help to PPS-binding B cells. The result is 
conversion of the B cell response from a T-independent to a T-dependent response 
with the advantage of follicular B cell activation, germinal centre formation, affinity 
maturation, class switching and the generation of a long lasting T cell-dependent 
memory response [143,310]. This bypasses some of the difficulties associated with 
use of the T cell-independent PPV in healthy children under 2 years of age in whom 
the immune system is not yet able to generate T cell-independent responses and 
results in good immunogenicity [311] and protection against invasive disease 
[312,313] in this population. The role of this vaccine in protection against IPD in 
older children and adults is currently under review. 
 
The T cell-dependent nature of the immune response to PCV is likely to be of benefit 
in the immunocompromised including HIV-infected patients, who, through 
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mechanisms already discussed, have impaired B cell responsiveness and limited 
ability to generate T-independent responses [119]. However, evidence for increased 
immunogenicity in this patient group remains controversial. In HIV-infected adults, 
study findings are largely inconsistent and comparison is challenging due to different 
schedules and combinations of pneumococcal immunisation. Most studies 
demonstrate improved antibody response in HIV-uninfected compared to infected 
individuals [184,185]. PCV has nevertheless been associated with a reduction in 
vaccine-serotype IPD in HIV-infected adults even not on treatment [186], though the 
limited serotype coverage of conjugate vaccines remains an issue of concern.  
In children, analysis of the evidence is confounded by differences in vaccine 
formulation, dosing schedule, age, disease and treatment status at immunisation and 
epidemiological factors (reviewed in [165]). Data from South Africa [314,315] 
suggest that reduced immunogenicity in HIV-infected children is manifest only when 
not treated with ART. This is confirmed by a study by Nachman et al. [316] in the 
United States, also showing similar immunogenicity between HIV-infected but 
ART-treated infants and healthy control infants. Concerns regarding persistence of 
PCV-generated immunity exist [317,318]), however. Only one study has examined 
clinical efficacy. This South African randomised placebo controlled trial [319] 
showed that PCV was efficacious in preventing vaccine serotype-specific IPD in 
HIV-infected infants in all patients and showed non-significant reductions in 
mortality. Five year follow up of the same study [320], however, showed reduced 
efficacy in the HIV-infected group compared to the control group.  
 
Little work has been done to compare directly the efficacy of PPV and PCV. Ahmed 
et al. [184] showed that in uninfected individuals, conjugate vaccine resulted in 
greater antibody concentrations than PPV, whereas in HIV-infected individuals there 
were no differences in immune response comparing the two vaccine types. Ho and 
colleagues [321], in South America, showed that both PPV23 and PCV7 were safe 
and immunogenic in HIV-infected adults, and that PCV7 was more immunogenic 
than PPV, eliciting greater and more persistent antibody concentrations for several 
serotypes. In a small number of HIV-infected infants and children, 5-valent PCV was 
more immunogenic than PPV [322]. A prime-boost strategy is also of interest, using 
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PCV to prime the immune response and subsequent PPV administration to boost it 
and possibly recruit the additional serotypes present in PPV. Sequential vaccination 
with PCV and PPV led to greater antibody concentrations than reached after 
vaccination with PPV alone in HIV-infected adults in one study [323].  
4.1.3 Evaluation of PPS-specific serum IgM and IgG concentration 
 
As discussed in Chapter 1, the immune response to pneumococcal infection and 
immunisation is complex. IgM anti-pneumococcal antibody is a polymeric antibody 
which binds to pneumococcal capsular antigens. Unmutated IgM [324], also known 
as natural antibody, is thought to exist even without antigenic stimulation, and is 
relatively non-specific (reviewed in [325]). Mutated IgM PPS-specific antibody is 
believed to be produced by marginal zone memory cells (reviewed in [135]); the 
need for antigenic stimulation to drive this is unclear, but may result from 
longstanding pneumococcal nasopharyngeal colonisation or from natural infection or 
pneumococcal polysaccharide vaccine. Cross-linking of the B cell receptor of newly 
recruited short lived antigen-specific B cells by PPS is thought to drive rapid 
differentiation to plasma cells, which continue to secrete anti-pneumococcal IgM 
antibody (reviewed in [310]).  Measurement of PPS-specific IgM concentrations, 
therefore, may provide an index of pre-existing natural and MZM immunity, in 
addition to representing an acute response to immunisation.  
IgG antibody is the isotype found most frequently in the human circulation and is 
synthesised and secreted by plasma cells after class switching has occurred, as part 
of the adaptive immune response. IgG is produced mainly by T-dependent pathways. 
Long term production of IgG in response to a particular antigen relies on a 
combination of antibody production by long lived, terminally differentiated, plasma 
cells and the maintenance of a population of memory cells. These cells have 
undergone a germinal centre reaction with affinity maturation, and can rapidly 
differentiate into short lived, IgG secreting, plasma cells if the cognate antigen is re-
encountered (reviewed in [326]). Measurement of circulating PPS-specific IgG, 
therefore, may represent the generation of effective long lived memory and plasma 
cell populations following the GC reaction, in response to both colonisation and 
natural Pnc infection. Although PPV immunisation is not considered to result in 
significant generation of primary long lived IgG-mediated immunity, it is thought 
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that PPV can boost pre-existing IgG memory [292]. In addition, there is increasing 
evidence that Pnc-specific IgM may have an important role in promoting the 
generation of long lasting, IgG-mediated, switched memory [190,191], possibly 
through its role in antigenic localisation to the spleen [189], promoting the GC centre 
reaction required to generate long-lived memory and plasma cells secreting Pnc-
specific IgG.  
 
In individuals with HIV infection, both MZM and switched memory B cell 
populations are known to be impaired, as discussed in Chapter 1 and shown in 
Chapter 3 of this thesis. Evaluation of PPS-specific IgM and IgG concentrations, 
pre- and post-immunisation with PPV, and comparison to healthy controls, provides 
some insight into the impaired immune response in HIV infection to this important 
pathogen. 
4.2 Methods 
 
The methods are fully described in Chapter 2, section 2.9. Baseline serum samples 
were taken pre-immunisation to evaluate for evidence of natural and pre-existing 
MZM immunity and PPV was then used to assess the ability of CON, HIV-V and 
HIV-H to generate and / or boost both short (IgM) and longer lived (IgG) serological 
memory responses. This was assessed by measurement of IgM and IgG antibody 
concentration in the blood at baseline, 28 days and one year after immunisation. 
Briefly, quantification of pneumococcal polysaccharide serotype-specific IgM and 
IgG was performed using an established flow based multiplex assay at the Clinical 
Immunology laboratory, Papworth Hospital NHS Trust. The assay is based on a 
method described by Lal et al. [246], in which individual carboxylated fluorescent 
beads were coated with serotype specific pneumococcal capsular polysaccharide. A 
pre-absorption stage with cell wall polysaccharide [247]
 
and serotype 22F [248] was 
performed to eliminate cross-reactive binding. Beads were then analysed by flow 
cytometry and pneumococcal PS binding activity quantified.  
The percentage of serotypes to which the subject has a putatively protective 
concentration of antibody is a useful index of protection. Cut-off serum 
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concentration levels in this study have been defined as an antibody concentration 
greater than a) 0.35 µg/ml and b) 1.3 µg/ml. These values are arbitrary and were 
selected to correspond to the titres of IgG antibody which are considered by the 
World Health Organization to be clinically protective against pneumococcal 
infection and/or colonisation [327] [328,329]. In the context of immunisation, the 
number of vaccine serotypes to which an individual responds has also been used to 
diagnose antibody deficiency. Depending on the number of serotypes assessed, a 
response to less than 50-70% of vaccine serotypes is considered to be indicative of 
antibody deficiency [330,331].  
A possible impact of viral control in early life was also considered. A comparison 
was performed between those HIV-V subjects who had achieved and maintained an 
undetectable viral load before the age of 10 years (HIV-V
E
), and those who were 
aviraemic at the time of sampling but without a history of early viral control <10y of 
age (HIV-V
-
).  
4.3 Results 
 
Samples taken at baseline, D28 and 1 year were analysed for serotype-specific IgM 
and IgG in all subject groups (shown in Table 4.1). The relationship between pre-
vaccination immunity and vaccine responsiveness was explored and compared 
between the cohorts. 
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   HIV infected 
subjects 
  CON HIV-V HIV-H 
n (samples available for serology) Samples at any timepoint 
combination 
52 64 26 
 D0 sample 51 63 25 
 D28 sample 49 12 6 
 1y sample 48 53 17 
 Paired D0 - D28 49 12 6 
 Paired D0 - 1y 48 52 17 
 Paired D28 –1y 47 10 5 
 Paired all timepoints 45 10 5 
Viral load undetectable at time of first 
sample (n) 
  34 14 
Viral load detectable at time of first 
sample (n) 
  29 11 
Viral load unknown (n)    1 0 
Table 4.1. Samples included in serological analysis. 
 
4.3.1 IgM anti-pneumococcal antibody 
 
Antibody concentration at baseline, day 28 and 1 year after immunisation with PPV 
 
IgM antibody concentrations are shown at baseline and at 28 days and 1 year after 
immunisation in all subject groups (Figure 4.1). Matched pair analysis showed the 
same pattern as analysis of the entire cohort, thus data from all subjects regardless of 
matching status is shown. IgM antibody was present at baseline for all cohorts. All 
cohorts achieved an increase in concentration 28 days after immunisation compared 
to the baseline (with the exception of a single serotype, 6B, in the HIV-H cohort); 
however this was significant for all serotypes only in the control group
2
 with four 
and two serotype-specific IgM concentrations not rising significantly in HIV-V
3
 and 
HIV-H
4
 groups respectively. This pattern was maintained at one year in all groups, 
                                                     
2
 p < 0.001 for all serotypes except 23F where p = 0.01 
3
 p values for serotypes as follows: 0.007 (1), 0.028 (4), 0.158 (5), 0.062 (6B), 0.041 (7F), 0.504 (14), 
0.272  (19F), 0.011 (23F) 
4
 p values for all serotypes as follows: 0.043 (1), 0.043 (4), 0.043 (5), 0.043 (6B), 0.043 (7F), 0.144 
(14), 0.043 (19F), 0.225 (23F) 
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with a significant increase in all serotypes in the control group
5
  and less serotype 
coverage in HIV-V
6
 and HIV-H
7
. 
                                                     
5
 p < 0.001 for all serotypes except 23F where p = 0.012 
6
 p values for all serotypes as follows: < 0.001 (1), < 0.001 (4), < 0.001 (5), < 0.001 (6B), 0.057 (7F), < 
0.001 (14), 0.176 (19F), < 0.001 (23F) 
7
 p values for all serotypes as follows: 0.015 (1), 0.001 (4), 0.003 (5), 0.023 (6B), 0.394 (7F), 0.023 
(14), 0.018 (19F), 0.152 (23F) 
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Figure 4.1: Serum IgM concentration (ug/ml, GMT with 95% CI) in all groups. 
The 0.35µg/ml and 1.3µg/ml IgM concentrations are shown by the solid line. *: p < 0.05 for the comparison 
between D0 and D28 (bottom) and D0 and 1y (top). 
 
102 
 
Between-group comparisons (shown in Table 4.2) showed that IgM concentration 
was significantly greater at baseline in the control group than HIV-V in six 
serotypes
8
, and greater than HIV-H (though not significantly so) in four serotypes
9
. 
IgM was greater in the controls than HIV-V
10
 and HIV-H
11
 in 7 and 6 serotypes 
respectively at a month and greater than HIV-V in all serotypes
12
 and HIV-H in 5 
serotypes
13
 at a year after immunisation. The difference between healthy control and 
HIV-infected cohorts was most marked in the increase in antibody concentration at 
day 28 compared to baseline levels. There was a trend to slightly greater values in 
HIV-H than HIV-V at all timepoints, although this was not consistent across all 
serotypes and rarely reached significance
14
. 
  
                                                     
8
 p values for all serotypes as follows: 0.193 (1), < 0.001 (4), 0.011 (5), 0.017 (6B), 0.028 (7F), 0.020 
(14), 0.125 (19F), 0.031 (23F) 
9
 p values for all serotypes as follows: 0.188 (1), 0.125 (4), 0.691 (5), 0.930 (6B), 0.670 (7F), 0.634 
(14), 0.131 (19F), 0.462 (23F) 
10
 p values for all serotypes as follows: 0.001 (1), < 0.001 (4), < 0.001 (5), 0.001 (6B), 0.013 (7F), 0.001 
(14), 0.003 (19F), 0.078 (23F) 
11
 p values for all serotypes as follows: 0.004 (1), 0.068 (4), 0.015 (5), 0.020 (6B), 0.031 (7F), 0.229 
(14), 0.020 (19F), 0.022 (23F) 
12
 p values for all serotypes as follows: < 0.001 (1), < 0.001 (4), 0.007 (5), < 0.001 (6B), < 0.001 (7F), 
0.004 (14), < 0.001 (19F), 0.020 (23F) 
13
 p values for all serotypes as follows: < 0.001 (1), 0.056 (4), 0.725 (5), 0.002 (6B), < 0.001 (7F), 0.511 
(14), < 0.001 (19F), 0.044 (23F) 
14
 p values for all serotypes as follows: 
D0: 0.617 (1), 0.133 (4), 0.047 (5), 0.028 (6B), 0.089 (7F), 0.011 (14), 0.640 (19F), 0.366 (23F) 
D28 0.646 (1), 0.799 (4), 0.037 (5), 0.442 (6B), 0.721 (7F), 0.195 (14), 0.799 (19F), 0.279 (23F)  
1y: 0.201 (1), 0.888 (4), 0.099 (5), 0.796 (6B), 0.225 (7F), 0.119 (14), 0.264 (19F), 0.662 (23F) 
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Serotype D0 D28 1y 
 CON HIV-V HIV-H CON HIV-V HIV-H CON HIV-V HIV-H 
N 51 63 25 49 12 6 48 53 17 
1 0.53 
(0.39-
0.72) 
0.42 
(0.34-
0.51) 
0.38 
(0.28-
0.50) 
3.27 
(2.52-
4.01) 
1.13* 
(0.66-
1.92) 
0.94* 
(0.33-
2.65) 
2.22 
(1.82-
2.71) 
0.78* 
(0.61-
1.00) 
0.58* 
(0.34-
0.99) 
4 0.22 
(0.14-
0.34) 
 
0.09* 
(0.06-
0.12) 
0.14 
(0.09-
0.24) 
1.09 
(0.78-
1.53) 
0.23* 
(0.11-
0.51) 
0.36 
(0.07-
1.84) 
0.61 
(0.45-
0.83) 
0.21* 
(0.15-
0.31) 
0.26 
(0.10-
0.66) 
5 0.54 
(0.39-
0.74) 
0.35* 
(0.27-
0.44) 
0.56† 
(0.41-
0.77) 
2.23 
(1.76-
2.81) 
0.41* 
(0.24-
0.70) 
0.94*† 
(0.51-
1.71) 
1.17 
(0.90-
1.52) 
0.63* 
(0.44-
0.89) 
1.05 
(0.60-
1.84) 
6B 0.24 
(0.061-
0.35) 
0.14* 
(0.11-
0.19) 
0.26† 
(0.17-
0.39) 
0.82 
(0.59-
1.14) 
0.16* 
(0.07-
0.37) 
0.26* 
(0.10-
0.62) 
0.60 
(0.43-
0.84) 
0.21* 
(0.15-
0.30) 
0.24* 
(0.15-
0.40) 
7F 0.76 
(0.51-
1.11) 
0.59* 
(0.46-
0.76) 
0.88 
(0.64-
1.20) 
2.17 
(1.67-
2.83) 
1.12* 
(0.63-
2.01) 
1.18* 
(0.69-
2.02) 
1.43 
(1.10-
1.84) 
0.69* 
(0.54-
0.87) 
0.56* 
(0.40-
0.79) 
14 0.39 
(0.25-
0.61) 
0.23* 
(0.16-
0.33) 
0.50† 
(0.33-
0.78) 
1.53 
(1.04-
2.26) 
0.34* 
(0.14-
0.79) 
0.81 
(0.19-
3.55) 
0.97 
(0.65-
1.44) 
0.41* 
(0.26-
0.65) 
0.80 
(0.42-
1.51) 
19F 0.68 
(0.47-
0.98) 
0.59 
(0.45-
0.77) 
0.57 
(0.41-
0.81) 
2.01 
(1.51-
2.68) 
0.73* 
(0.40-
1.30) 
0.64* 
(0.23-
1.77) 
1.67 
(1.25-
2.23) 
0.67* 
(0.49-
0.91) 
0.54* 
(0.32-
0.90) 
23F 0.16 
(0.11-
0.24) 
0.09* 
(0.07-
0.13) 
0.13 
(0.07-
0.25) 
0.42 
(0.30-
0.59) 
0.26 
(0.12-
0.52) 
0.15* 
(0.07-
0.30) 
0.28 
(1.89-
0.40) 
0.16* 
(0.11-
0.23) 
0.15* 
(0.07-
0.33) 
Table 4.2. Serum IgM concentration.  
Serum IgM antibody concentration (µg/ml, GMT, with 95% CI) by serotype at D0, D28 and 1 year is shown for 
each patient cohort. n = number of samples included in the analysis. *: p < 0.05 for the comparison with CON at 
same timepoint †: p < 0.05 for the comparison between HIV-V and HIV-H at same timepoint.  
 
Spread of data and serotype dominance was similar in all cohorts both pre- and post-
immunisation with PPV (data not shown), with lower IgM responses to serotypes 4, 
6B and 23F and greater responses to serotypes 1, 5, 7F and 19F.  
Correlation of IgM concentration at baseline, day 28 and 1 year after immunisation 
were assessed, to identify whether baseline concentration was predictive of 
subsequent short or longer term IgM response (Table 4.3). Baseline IgM 
concentration did not predict the IgM response at 28 days post immunisation in any 
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subject group. There was, however, a positive correlation between baseline IgM 
concentration and IgM response at 1 year, in all groups, suggesting an association 
between the pre-immunisation concentration of IgM and the subsequent longer term 
IgM response.  
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 D0 vs D28 D0 vs 1y D28 vs 1y 
 CON HIV-V HIV-H CON HIV-V HIV-H CON HIV-V HIV-H 
 r p r P r p r p r p r p r p r p R p 
1 0.025 0.867 0.032 0.923 0.051 0.935 0.099 0.512 0.488* 0.000 0.523* 0.045 0.176 0.248 -0.091 0.803 0.600 0.400 
4 0.095 0.516 0.360 0.250 0.359 0.553 0.457* 0.001 0.730* 0.000 0.776* 0.001 0.304* 0.042 0.037 0.920 0.800 0.200 
5 0.116 0.427 0.144 0.656 0.600 0.285 0.535 0.213 0.565* 0.000 0.864* 0.000 0.192 0.206 -0.261 0.467 0.400 0.600 
6B 0.045 0.760 0.638* 0.025 0.400 0.505 0.487* 0.008 0.797* 0.000 0.968* 0.000 0.429* 0.003 -0.134 0.713 0.400 0.600 
7F 0.253 0.080 -0.410 0.186 0.300 0.624 0.385* 0.049 0.653* 0.000 0.304 0.271 0.370* 0.012 -0.394 0.260 0.200 0.800 
14 0.094 0.521 0.357 0.255 -
0.300 
0.624 0.483 0.123 0.793* 0.000 0.770* 0.001 0.366* 0.013 0.036 0.920 0.800 0.200 
19F 0.207 0.153 0.441 0.152 0.400 0.505 0.344 0.162 0.775* 0.000 0.574* 0.025 0.395* 0.007 0.067 0.855 0.400 0.600 
23 0.255 0.076 0.855* 0.000 0.100 0.873 0.446* 0.002 0.878* 0.000 0.751* 0.001 0.508* 0.000 0.854* 0.002 0.800 0.200 
Table 4.3. Correlation analysis of IgM concentrations at various timepoints for all cohorts. 
r values and p values are shown for each cohort for each serotype. *: p < 0.05 
 
DISCARD THIS PAGE  
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Serotype coverage 
 
The percentage of subjects in each group responding to at least 70% of serotypes 
with serum IgM concentration of >0.35 ug/ml and >1.3 ug/ml was examined (Figure 
4.2) and showed marked differences between patient groups
15,16
. At one year post 
immunisation, 80.4% of control subjects, 37.7% of vertically infected and 53.3% of 
horizontally infected patients had achieved concentrations exceeding 0.35 µg/ml in 
more than 70% of serotypes; this dropped to 15.2% in controls and 1.89% and 0.0% 
in vertically and horizontally infected patients respectively when the higher cut off of 
1.3 µg/ml was examined.  
 
 
Figure 4.2. >70% serotype coverage - IgM. 
The percentage of subjects with > 70% serotypes reaching serum IgM concentration of a) >0.35 µg/ml, b) >1.3 
µg/ml, in each group, is shown at D0, D28 and 1y. n = 51, 49, 48 (CON); 63, 12, 53 (HIV-V), and 25, 6, 17 
(HIV-H), at D0, D28 and 1y respectively. *: p < 0.05 for the comparison between groups at each timepoint. 
 
The average percentage of serotypes with IgM concentration >0.35 µg/ml and 1.3 
µg/ml was also examined in each subject group (Figure 4.3) and showed a clear 
trend for control subjects to achieve a greater percentage of serotype coverage at all 
                                                     
15
 0.35ug/ml cut off: p values for all timepoints as follows: 
CON cf HIV-V: < 0.001 (D0), 0.263(D28), < 0.001 (1y) 
CON cf HIV-H: 0.244 (D0), 0.266 (D28), 0.05 (1y) 
HIV-V cf HIV-H: 0.178 (D0), 1.00 (D28), 0.279 (1y) 
 
16
 1.3ug/ml cut off: p values for all timepoints as follows: 
CON cf HIV-V: 0.037 (D0), 0.022 (D28), 0.023 (1y) 
CON cf HIV-H: 0.571  (D0), 0.380 (D28), 0.325 (1y) 
HIV-V cf HIV-H: N/A (D0), 0.515 (D28), 1.00 (1y) 
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timepoints than HIV-infected groups. Using a cut off of 0.35 µg/ml
17
, at baseline, 
mean serotype coverage was reduced in the HIV infected cohorts compared with 
controls and whilst serotype coverage increased at D28 post immunisation, the 
increase was less in the disease groups. By 1 year, mean serotype coverage in all 
groups had fallen only slightly in all groups, again with lower mean serotype 
coverage in both disease groups. When the higher cut off of 1.3 µg/ml was 
examined
18
, mean serotype coverage at baseline in CON was 18.38%, HIV-V 7.54% 
and HIV-H 11.25%. At one month, mean serotype coverage in HIV-V and HIV-H 
was lower than in CON and this pattern persisted at 1y. When both responses to 
more than 70% of serotypes and percentage of serotype coverage was considered, 
there was a trend to a greater response of HIV-H than HIV-V subjects at both 
response levels but this did not reach statistical significance.   
 
Figure 4.3: Percentage serotype coverage – IgM. 
The percentage of serotypes (mean with 95% CI) against which IgM concentration reaches a) >0.35 µg/ml, b) 
>1.3 µg/ml is shown at each timepoint. n = 51, 49, 48 (CON); 63, 12, 53 (HIV-V), and 25, 6, 17 (HIV-H), at D0, 
D28 and 1y respectively. *: p < 0.05 for the comparison between groups at each timepoint.  
 
                                                     
17
 p values for all timepoints as follows: 
CON cf HIV-V: 0.016 (D0), < 0.001 (D28), < 0.001 (1y) 
CON cf HIV-H: 0.253 (D0), < 0.001 (D28), 0.001 (1y) 
HIV-V cf HIV-H: 0.203 (D0), 0.624 (D28), 0.565 (1y) 
 
18
 p values for all timepoints as follows: 
CON cf HIV-V: < 0.001 (D0), < 0.001 (D28), < 0.001 (1y) 
CON cf HIV-H: 0.160 (D0), < 0.001 (D28), < 0.001 (1y) 
HIV-V cf HIV-H: < 0.001 (D0), 0.228 (D28), 0.829 (1y) 
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Viral control – current and in childhood 
The association between HIV viraemia (at the time of sampling) and IgM 
concentration was examined at all timepoints. There was no difference in IgM 
profile between those subjects with detectable viral load at the time of sampling, and 
those with effective viral control (data not shown), except in the case of HIV-V for 
selected serotypes, where IgM concentration was lower in those with detectable VL 
at D0 for 19F (p = 0.005) and D28 for serotypes 4 and 5 (p value = 0.042 and 0.012 
respectively).  
When patients who had achieved viral control early (HIV-V
E
) were assessed, there 
was no difference in baseline IgM (except in serotype 19F; p = 0.037) and a trend 
towards increased IgM concentration in all serotypes at 1 year after immunisation 
compared to those with current but not early viral control (HIV-V
-
), shown in Table 
4.4. There was also an increase in the percentage of serotypes with antibodies above 
the levels of 0.35 µg/ml and 1.3 µg/ml in HIV-V
E 
compared to HIV-V
- 
(p < 0.001 
and p = 0.035 respectively), at 1 year after immunisation (Table 4.5).  
 D0  1y  
 HIV-VE HIV-V- HIV-VE HIV-V- 
n 7 27 7 29 
1 0.41 0.38 1.52 0.80 
4 0.12 0.12 0.41 0.27 
5 0.35 0.45 1.24 0.79 
6B 0.23 0.21 0.43 0.23 
7F 0.74 0.67 1.17 0.62 
14 0.48 0.34 1.88* 0.47 
19F 1.32* 0.75 1.41 0.68 
23F 0.13 0.09 0.34 0.17 
Table 4.4. Early-life viral control and serum IgM concentration  
Serum IgM antibody concentration (µg/ml; GMT) by serotype at D0 and 1 year is shown for HIV-VE and HIV-V-
. n = number of samples included in the analysis. *: p < 0.05 for the comparison between HIV-VE and HIV-V-. 
 
 HIV-VE HIV-V- 
Mean % serotypes >0.35µg/ml   
D0 42.86 46.76 
1y 80.36* 54.33 
Mean % serotypes >1.3µg/ml   
D0 14.29 9.72 
1y 32.14* 18.75 
Table 4.5. Early-life viral control and serotype coverage (IgM) 
* p < 0.05 for comparison between HIV-VE and HIV-V- 
There was no correlation with CD4
+
 cell count and IgM concentration at any 
timepoint in either HIV-infected group (data not shown). 
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4.3.2 IgG anti-pneumococcal antibody 
 
Concentrations at baseline, day 28 and 1 year after immunisation with PPV 
IgG antibody concentrations are shown at baseline and at 28 days and 1 year after 
immunisation in all subject groups (Figure 4.4). As with the IgM data, analysis 
including only those subjects with matched timepoint samples showed a similar 
pattern.  
IgG was detectable prior to immunisation for all cohorts and increased 28 days after 
immunisation for all serotypes in the control
19
 and HIV-V group
20
, and for eight of 
the ten serotypes in HIV-H
21
. By 1 year after immunisation, IgG concentration was 
greater than at baseline against all serotypes for CON
22
, HIV-V
23
 and all but one 
serotype for HIV-H
24
.  
                                                     
19
 p values < 0.001 for all serotypes  
20
 p values for all serotypes as follows: 0.028 (1), 0.005 (4), 0.012 (5), 0.028 (6B), 0.005 (7F), 0.005 
(9V), 0.036 (14), 0.005 (18C), 0.017 (19F), 0.018 (23F) 
21
 p values for all serotypes as follows: 0.028 (1), 0.028 (4), 0.075 (5), 0.043 (6B), 0.028 (7F), 0.028 
(9V), 0.043 (14), 0.028 (18C), 0.249 (19F), 0.043 (23F) 
22
 p values < 0.001 for all serotypes 
23
 p values < 0.001 for all serotypes 
24
 p values for all serotypes as follows: 0.001 (1), 0.005 (4), 0.055 (5), 0.003 (6B), 0.000 (7F), 0.001 
(9V), 0.005 (14), 0.002 (18C), 0.007 (19F), 0.023(23F) 
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 Figure 4.4: Serum IgG concentration (ug/ml, GMT with 95% CI) in all groups.    
The 0.35 µg/ml and 1.3 µg/ml IgG concentrations are shown by the solid line. *: p < 0.05 for the comparison 
between D0 and D28 (bottom) and D0 and 1y (top). 
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IgG concentration was greater in the control group than in the HIV-infected cohorts 
(Table 4.6) at all bleed points for a number of serotypes and this difference increased 
following immunisation such that by 1y post immunisation, serum IgG concentration 
was greater in the control group compared with the HIV cohorts for all serotypes 
analysed
25
. The difference between control and HIV-infected groups was greatest at 
day 28 for most serotypes. There was a trend to slightly greater IgG concentration in 
HIV-H than HIV-V disease group, particularly at D28, although this was not 
consistent across all serotypes and rarely reached significance
26
.  
 
 
 
 
 
 
                                                     
25
 p values for all serotypes as follows: 
D0: 
CON cf HIV-V:  0.632 (1), < 0.001 (4), 0.949 (5), 0.000 (6B), 0.021 (7F), < 0.001 (9V), 0.003 (14), 0.000 
(18C), 0.914 (19F), < 0.001 (23F) 
CON cf HIV-H: 0.816 (1), 0.039 (4), 0.952 (5), 0.103 (6B), 0.065 (7F), 0.016 (9V), 0.914 (14), 0.006 
(18C),  0.912 (19F), 0.151 (23F) 
D28: 
CON cf HIV-V: < 0.001 (1), < 0.001 (4), < 0.001 (5), 0.000  (6B), 0.004 (7F), < 0.001 (9V), < 0.001 (14), < 
0.001 (18C),  0.098 (19F), 0.001 (23F) 
CON cf HIV-H: 0.186(1), 0.025 (4), 0.215 (5), 0.002 (6B), 0.052 (7F), 0.059 (9V), 0.039 (14), 0.003 
(18C),  0.092(19F), 0.072 (23F) 
1y: 
CON cf HIV-V: < 0.001 (1), < 0.001 (4), 0.001 (5), < 0.001 (6B), < 0.001 (7F), < 0.001 (9V), < 0.001 (14), 
< 0.001 (18C),  < 0.001 (19F), < 0.001 (23F) 
CON cf HIV-H: 0.001 (1), < 0.001 (4), 0.002 (5), 0.001 (6B), 0.016 (7F), < 0.001 (9V), 0.002 (14), < 
0.001 (18C), 0.002 (19F), < 0.001 (23F) 
 
 
26
 p values for all serotypes as follows: 
D0: 0.771 (1), 0.281 (4), 0.917 (5), 0.040 (6B), 0.683 (7F), 0.468 (9V), 0.003 (14), 0.070 (18C), 0.827 
(19F),0.001  (23F) 
D28: 0.256 (1), 0.404 (4), 0.048 (5), 0.462 (6B), 0.808 (7F), 0.098 (9V), 0.180 (14),  0.301 (18C),  0.350 
(19F), 0.404  (23F) 
1y: 0.963(1), 0.811  (4), 0.426 (5), 0.225 (6B), 0.343 (7F), 0.564 (9V), 0.145 (14), 0.422 (18C), 0.691 
(19F), 0.432 (23F) 
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Serotype D0 D28 1y 
 CON HIV-V HIV-H CON  HIV-V HIV-H CON HIV-V HIV-H 
n 51 63 25 49 12 6 48 53 17 
1 0.31 
(0.18-
0.51) 
0.23 
(0.16-
0.33) 
0.21 
(0.13-
0.35) 
4.20 
(3.12-
5.54) 
0.73* 
(0.27-
2.01) 
1.99 
(0.43-
9.16) 
3.23 
(2.28-
4.58) 
0.80* 
(0.55-
1.16) 
0.74* 
(0.34-
1.59) 
4 0.10 
(0.06-
0.14) 
0.03* 
(0.03-
0.05) 
0.05* 
(0.03-
0.08) 
1.30 
(0.91-
1.85) 
0.23* 
(0.10-
0.54) 
0.35* 
(0.10-
1.19) 
0.78 
(0.53-
1.14) 
0.12* 
(0.09-
0.17) 
0.12* 
(0.06-
0.26) 
5 0.31 
(0.21-
0.47) 
0.34 
(0.25-
0.45) 
0.30 
(0.23-
0.40) 
2.21 
(1.56-
3.14) 
0.49*† 
(0.36-
0.67) 
1.23 
(0.35-
4.31) 
1.66 
(1.13-
2.45) 
0.68* 
(0.47-
0.97) 
0.49* 
(0.26-
0.97) 
6B 0.28 
(0.16-
0.48) 
0.04* 
(0.03-
0.08) 
0.12 
(0.05-
0.31) 
3.73 
(2.54-
5.48) 
0.14* 
(0.03-
0.66) 
0.36* 
(0.05-
2.30) 
2.83 
(1.88-
4.24) 
0.22* 
(0.11-
0.43) 
0.53* 
(0.19-
1.48) 
7F 0.61 
(0.47-
0.81) 
0.35* 
(0.25-
0.48) 
0.39 
(0.25-
0.59) 
3.47 
(2.55-
4.72) 
1.04* 
(0.42-
2.58) 
1.30 
(0.29-
5.84) 
2.53 
(1.88-
3.38) 
0.79* 
(0.57-
1.10) 
1.05* 
(0.57-
1.91) 
9V 0.31 
(0.20-
0.49) 
0.11* 
(0.07-
0.16) 
0.12*† 
(0.07-
0.23) 
2.68 
(1.96-
3.66) 
0.44* 
(0.24-
0.80) 
1.10 
(0.39-
3.14) 
2.13 
(1.55-
2.94) 
0.42* 
(0.28-
0.64) 
0.30* 
(0.16-
0.58) 
14 0.21 
(0.10-
0.45) 
0.05* 
(0.03-
0.09) 
0.25† 
(0.09-
0.65) 
5.94 
(3.83-
9.20) 
0.39* 
(0.07-
2.23) 
1.40* 
(0.10-
19.4) 
6.34 
(4.01-
10.04) 
0.24* 
(0.11-
0.56) 
0.79* 
(0.20-
3.14) 
18C 0.47 
(0.33-
0.68) 
0.13* 
(0.10-
0.17) 
0.22* 
(0.15-
0.33) 
2.92 
(2.07-
4.14) 
0.26* 
(0.12-
0.59) 
0.55* 
(0.18-
1.67) 
2.28 
(1.62-
2.23) 
0.30* 
(0.21-
0.41) 
0.41* 
(0.23-
0.75) 
19F 0.50 
(0.31-
0.81) 
0.49 
(0.31-
0.76) 
0.45 
(0.22-
0.91) 
3.56 
(2.48-
5.13) 
2.13 
(1.15-
3.98) 
1.43 
(0.53-
3.88) 
2.84 
(1.96-
4.12) 
0.81* 
(0.52-
1.28) 
0.63* 
(0.24-
1.65) 
23F 0.27 
(0.16-
0.46) 
0.04* 
(0.02-
0.06) 
0.13† 
(0.07-
0.26) 
2.03 
(1.39-
2.96) 
0.17* 
(0.04-
0.78) 
0.45 
(0.05-
4.10) 
1.57 
(1.07-
2.31) 
0.13* 
(0.07-
0.24) 
0.19* 
(0.07-
0.53) 
Table 4.6. Serum IgG concentration.  
Serum IgG antibody concentration (µg/ml, GMT, with 95% CI) by serotype at D0, D28 and 1 year is shown for 
each patient cohort. n = number of samples included in the analysis. *: p < 0-.05 for the comparison with CON at 
same timepoint †: significance at p < 0.05 for the comparison between HIV-V and HIV-H at same timepoint.  
 
As with the IgM data, spread of data and serotype dominance was similar at all 
timepoints and across all groups (data not shown).  
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To determine whether pre-existing IgG concentration predicted response to the 
vaccines, the correlation between baseline and subsequent IgG concentration, and 
responses at day 28 and 1 year after immunisation was made (Table 4.7). This 
showed that pre-immunisation concentration correlated with response at 28 days 
post-immunisation more strongly than seen with IgM concentration in all cohorts 
and a positive correlation between baseline IgG and IgG response at 1 year was also 
seen. As with the IgM data, there was also some correlation between IgG 
concentration at day 28 and 1 year post-immunisation.  
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 D0 vs D28 D0 vs 1y D28 vs 1y 
 CON HIV-V HIV-H CON HIV-V HIV-H CON HIV-V HIV-H 
 r p r p r p r p r p r p r p r p r p 
1 0.369
* 
0.00
9 
0.673
* 
0.03
3 
0.812
* 
0.05
0 
0.792
* 
0.00
0 
0.386* 0.05 0.471 0.05
7 
0.418
* 
0.00
3 
0.667
* 
0.05
0 
0.900
* 
0.03
7 
4 0.329
* 
0.02
1 
0.355 0.31
4 
0.463 0.35
5 
0.628
* 
0.00
0 
0.424* 0.02 0.701
* 
0.00
2 
0.504
* 
0.00
0 
0.469 0.20
3 
0.900
* 
0.03
7 
5 0.386
* 
0.00
6 
0.199 0.58
2 
0.429 0.39
7 
0.589
* 
0.00
0 
0.620* 0.00
0 
0.677
* 
0.00
3 
0.524
* 
0.00
0 
0.008 0.98
3 
0.900
* 
0.03
7 
6B 0.321
* 
0.02
5 
0.643
* 
0.04
5 
0.655 0.15
8 
0.733
* 
0.00
0 
0.743* 0.00
0 
0.381 0.13
1 
0.377
* 
0.00
9 
0.648 0.05
9 
0.900
* 
0.03
7 
7F 0.644
* 
0.00
0 
0.742
* 
0.01
4 
0.714 0.11
1 
0.620
* 
0.00
0 
0.660* 0.00
0 
0.656
* 
0.00
4 
0.625
* 
0.00
0 
0.962
* 
0.00
0 
0.70 0.08
8 
9V 0.072 0.63
5 
0.818
* 
0.00
4 
0.771 0.07
2 
0.596
* 
0.00
0 
0.0588
* 
0.00
0 
0.745
* 
0.00
1 
0.247 0.09
4 
0.711
* 
0.03
2 
1.000
* 
0.00
0 
14 0.141 0.33
3 
0.180 0.61
9 
0.334 0.51
8 
0.634
* 
0.00
0 
0.705* 0.00
0 
0.419 0.09
4 
0.321
* 
0.02
8 
0.426 0.25
3 
0.900
* 
0.03
7 
18
C 
0.400
* 
0.00
4 
0.857
* 
0.00
2 
0.314 0.54
4 
0.793
* 
0.00
0 
0.482* 0.00
0 
0.564
* 
0.01
8 
0.566
* 
0.00
0 
0.946
* 
0.00
0 
0.066
7 
0.21
9 
19
F 
0.184 0.20
6 
0.875
* 
0.00
1 
-
0.143 
0.78
7 
0.655
* 
0.00
0 
0.785* 0.*0
0 
0.814
* 
0.00
0 
0.390
* 
0.00
7 
0.833
* 
0005 0.300 0.62
4 
23 0.317
* 
0.02
7 
0.609 0.06
2 
0.986
* 
0.00
0 
0.758
* 
0.00
0 
0.717* 0.00
0 
 0.00
1 
 0.00
0 
0.894
* 
0.00
1 
0.900
* 
0.03
7 
Table 4.7. Correlation analysis of IgG concentrations at various timepointsfor all cohorts. 
r values and p values are shown for each cohort for each serotype. *: p < 0.05 
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Serotype coverage 
 
The percentage of subjects in each group with more than 70% of serotypes greater 
than the putative protective levels of a) 0.35 µg/ml and b) 1.3 µg/ml was examined. 
Serotype coverage was considerably greater in control subjects compared with HIV 
infected individuals (Figure 4.5). At one year post immunisation, 93.8% of control 
subjects, and 34.5% and 47.1% of vertically and horizontally infected patients 
respectively, had achieved PPS IgG concentrations exceeding 0.35 µg/ml in more 
than 70% of serotypes
27
; this dropped to 58.3% in controls and only 1.82% and 
11.8% in vertically and horizontally infected patients respectively when the higher 
cut off of 1.3µg/ml was used
28
 (Figure 4.5).   
 
Figure 4.5. 70% serotype coverage - IgG. 
The percentage of subjects with > 70% serotypes reaching serum IgG concentration of a) >0.35 µg/ml, b) >1.3 
µg/ml, in each group at D0, D28 and 1y is shown. n = 51, 49, 48 (CON); 63, 12, 53 (HIV-V), and 25, 6, 17 (HIV-
H), at D0, D28 and 1y respectively. *: p < 0.05 for the comparison between groups at each timepoint. 
 
                                                     
27
 p values for all timepoints as follows: 
CON cf HIV-V: 0.057 (D0), < 0.001 (D28), < 0.001 (1y) 
CON cf HIV-H: 0.270 (D0), 0.298 (D28), < 0.001 (1y) 
HIV-V cf HIV-H: 0.739 (D0), 0.304 (D28), 0.326 (1y) 
 
28
 p values for all timepoints as follows: 
CON cf HIV-V: N/A (D0), < 0.001 (D28),  < 0.001 (1y) 
CON cf HIV-H: N/A (D0), 0.002 (D28), 0.001 (1y) 
HIV-V cf HIV-H: N/A (D0), 0.353 (D28), 0.133 (1y) 
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As with IgM, the greater serotype coverage in the control group compared to HIV-
infected groups was seen both pre- and post-immunisation (Figure 4.6) using both 
the 0.35 µg/ml 
29
 and 1.3 µg/ml
30
 cut offs.  
 
Figure 4.6: Percentage serotype coverage - IgG. 
Percentage of serotypes (mean with 95% CI) against which IgG concentration reaches a) >0.35µg/ml, b) >1.3 
µg/ml at each timepoint. n = 51, 49, 48 (CON); 63, 12, 53 (HIV-V), and 25, 6, 17 (HIV-H), at D0, D28 and 1y 
respectively. *: p < 0.05 for the comparison between groups at each timepoint.  
 
The HIV-H cohort showed a trend towards greater serotype coverage than HIV-V 
but this did not reach significance
31
.   
Viral control – current and in childhood 
There was no difference in serotype-specific IgG concentration between those 
subjects with detectable viral load at the time of sampling, and those with viral 
control (data not shown), except in HIV-V, where concentration of serotype 1 IgG 
was greater at baseline in those with detectable VL (p = 0.028) and concentration of 
4, 6B, 9V and 14 were lower in those with detectable VL (p = 0.024, 0.039, 0.017 
                                                     
29
 p values for all timepoints as follows: 
CON cf HIV-V: 0.002 (D0), < 0.001 (D28),  < 0.001 (1y) 
CON cf HIV-H: 0.088 (D0), < 0.001 (D28), < 0.001 (1y) 
 
30
 p values for all timepoints as follows: 
CON cf HIV-V: 0.008 (D0), < 0.001 (D28), < 0.001 (1y) 
CON cf HIV-H:0.034 (D0), < 0.001 (D28), < 0.001 (1y) 
 
31
 p values for all timepoints as follows: 
0.35µg/ml cut off: HIV-V cf HIV-H: 0.181 (D0), 0.027 (D28), 0.395 (1y) 
1.3µg/ml cut off: HIV-V cf HIV-H: 0.645 (D0), 0.046 (D28), 0.273 (1y) 
 
 
117 
 
and 0.025 respectively) and in HIV-H where concentration of serotype 18C was 
lower in those with detectable VL at both  baseline (p = 0.025) and 1y (p = 0.023).  
When the HIV-V infected group was examined according to viral control in 
childhood, there was no difference in baseline IgG but a trend towards increased IgG 
concentration in all serotypes at 1 year after immunisation with PPV in HIV-V
E
 
compared to HIV-V
-
 (Table 4.8). There was also an increase in the percentage of 
serotypes with antibodies above the putative protective levels of 0.35 µg/ml and 1.3 
µg/ml in HIV-V
E 
compared to HIV-V
-
 (p < 0.001 and 0.004 respectively) at 1 year 
after immunisation (Table 4.9).  
 D0  1y  
 HIV-VE HIV-V- HIV-VE HIV-V- 
n 7 27 7 29 
1 0.20 0.17 1.24 0.90 
4 0.06 0.04 0.27 0.16 
5 0.32 0.32 1.76 0.69 
6B 0.50 0.10 1.73* 0.39 
7F 0.24 0.36 1.28 0.85 
9V 0.19 0.14 1.31* 0.54 
14 0.05 0.11 3.42 0.65 
18C 0.14 0.18 0.64 0.40 
19F 0.95 0.42 1.79 0.78 
23F 0.06 0.07 0.61 0.21 
Table 4.8. Early-life viral control and serum IgG concentration.  
Serum IgG antibody concentration (µg/ml; GMT) by serotype at D0 and 1 year is shown for HIV-VE and HIV-V-
. n = number of samples included in the analysis. *: p < 0.05 for the comparison between HIV-VE and HIV-V-. 
 
 
 HIV-VE HIV-V- 
Mean % serotypes >0.35µg/ml   
D0 34.29 32.00 
1y 77.14* 52.59 
Mean % serotypes >1.3µg/ml   
D0 11.43 11.60 
1y 42.86* 24.44 
Table 4.9. Early-life viral control and serotype coverage (IgG). 
* p < 0.05 for comparison between HIV-VE and HIV-V- 
There was no correlation with CD4
+
 cell count and IgG concentration at any 
timepoint in either HIV-infected cohort (data not shown). 
4.3.3 Correlation of IgM and IgG antibody concentration 
 
To explore the relationship between serotype specific IgM and IgG, the correlation 
between the pre-immunisation IgM concentration and post-immunisation IgG 
concentration (at 28 days and 1 year) was examined (Table 4.10). There was a 
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positive correlation between pre-immunisation IgM titre and IgG concentration at 1 
year post immunisation in HIV-V individuals. This was not seen in healthy controls 
or HIV-H subjects.   
 IgM D0 vs IgG D28 IgM D0 vs IgG 1y 
 CON HIV-V HIV-H CON HIV-V HIV-H 
 r p r p r p r p r p r P 
1 -0.112 0.442 0.692* 0.018 0.116 0.827 0.167 0.256 0.272* 0.045 0.052 0.844 
4 0.140 0.338 -0.160 0.639 -0.058 0.913 0.282 0.052 0.353* 0.009 0.510* 0.037 
5 0.170 0.243 -0.048 0.888 0.086 0.872 0.259 0.076 0.353* 0.009 0.263 0.309 
6B -0.058 0.692 -0.085 0.805 -0.600 0.208 -0.082 0.581 0.295* 0.030 0.207 0.424 
7F 0.203 0.162 0.169 0.620 -0.771 0.072 0.219 0.136 0.373* 0.005 -0.032 0.903 
14 0.148 0.311 -0.477 0.138 -0.086 0.872 0.325* 0.024 0.338* 0.012 -0.183 0.482 
19F 0.001 0.993 0.592 0.056 0.486 0.329 0.036 0.806 0.389* 0.004 0.139 0.596 
23 0.026 0.861 0.324 0.331 -0.486 0.329 0.174 0.236 0.382* 0.004 0.044 0.865 
 
Table 4.10. Correlation of baseline IgM and D28 and 1y IgG concentrations. 
r values and p values are shown for each cohort for each serotype. *. p < 0.05. 
 
4.3.4 Relationship between memory cell populations and serum antibody concentration  
 
To clarify whether the serum response to immunisation was related to abundance of 
memory B cell populations, the relationship between MZM and switched memory B 
cell percentage and IgM and IgG and was examined in all cohorts both pre and one 
year after immunisation with PPV. Subjects were divided into good and poor 
responders, based on achieving >70% serotype coverage with a cut off of either 0.35 
µg/ml or 1.3 µg/ml. A reduced proportion of MZM B cells was seen in those HIV-V 
patients defined as poor IgM responders at baseline, using a cut off of 0.35 µg/ml (p 
= 0.032), compared to those with higher baseline responses; this relationship was not 
seen in healthy controls or HIV-H subjects, or at 1 year after immunisation. 
 
4.4 Discussion 
 
I investigated the impact of vertically and horizontally acquired HIV infection on 
pre-existing immunity to PPS and the short and long term humoral immune response 
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to PPV. I found that both pre-existing and post-immunisation IgM and IgG responses 
were significantly impaired in both HIV cohorts, with some trend to lower antibody 
concentrations in the vertically infected cohort compared with their horizontally 
infected counterparts. Pre-existing IgM and IgG concentration predicted the longer 
term IgM and IgG responses respectively at one year, and in the case of the vertically 
infected cohort, pre-immunisation IgM predicted the concentration of IgG at 1 year 
after immunisation. Early sustained viral control was associated with greater serum 
antibody titres in the vertically infected cohort. 
I  have shown that IgM and IgG antibodies to pneumococcal capsule serotypes were 
present at baseline in both healthy control and HIV infected patients. IgM at 
baseline, in this previously unimmunised population, is likely to represent both 
natural, non-mutated antibody [324] and, probably, IgM secreted by marginal zone 
cells. IgG present at baseline is likely be produced by mutated memory cells [292] 
produced as a result of both prior colonisation and non-invasive infection with 
Streptococcus pneumoniae [152,153]. Increases in anti-Pnc antibodies were manifest 
at both one month and one year after immunisation with PPV in both healthy 
controls and HIV infected patients.  
Serum antibody concentrations were, in general, lower at all timepoints in both HIV-
infected cohorts than in controls. Lower baseline levels of IgM may represent defects 
in natural IgM immunity to Pnc, in addition to the documented effects on the 
marginal zone compartment [118,119]; previous studies have not directly examined 
the impact of HIV infection on natural IgM-mediated immunity to Pnc. Lower 
baseline levels of PPS-specific IgG have been shown in other studies [173] and may 
represent a failure in HIV to develop and/or maintain serological memory to 
previous infection and/or colonisation.  At both 28 days and one year post-
immunisation, the response to PPV vaccine was also of lower magnitude in HIV-
infected patients for both IgM and IgG isotypes than that seen in healthy controls. 
This is consistent with most existing data showing that, after immunisation with 
PPV, both adults [302] and children [332] with HIV infection mount a poorer 
response than healthy controls. Overall, this relatively poor IgM and IgG response to 
PPV may suggest impairment of both marginal zone and switched memory 
responses in HIV-infected patients. Impaired generation and boosting of memory 
responses may also result from poor generation of de novo responses by naïve cells, 
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due to hyperactivation [51], hyporeactivity to proliferation stimuli [26] and abnormal 
B cell trafficking [58].  
The poorer antibody response to PPV in our HIV-infected cohorts resulted in a very 
low proportion of both vertically and horizontally HIV-infected individuals reaching 
the putatively protective level of antibody concentration greater than 1.3 µg/ml in 
least 70% of serotypes tested at one year after immunisation. Whilst this study 
describes the concentration of antibody produced in response to PPV immunisation, 
there is also evidence for qualitative, as well as quantitative, defects in HIV 
infection, although this has mainly been examined in the context of the conjugate 
vaccine [314,315]. These qualitative defects are likely to further compound the 
compromised protection against pneumococcal infection in HIV-infected patients 
who have undergone immunisation and will be explored using serum from the 
cohorts described, in future studies.  
The role of viral control in protecting vaccine responses is unclear. There was no 
difference in the response of HIV-infected individuals by viraemic control at time of 
blood sampling. This is difficult to interpret in the context of existing literature. Few 
studies report the impact of viral load directly on the serological response to PPV. Of 
those that do, an independent association between high HIV viral load and low 
vaccine effectiveness has been reported [333]. However, other studies, looking at the 
impact of ART on vaccine response show that the vaccine has only a modest effect 
even with therapy (and thus (presumably) control of viral load) [302]. Other studies 
have been performed on patients not on ART, likely with uncontrolled viral load, 
preventing comparison of response according to viraemic status [307,334]. ART is 
known to reverse, at least partially, several of the immunological effects of HIV 
believed to underlie poor PPV efficacy, including VH3 repertoire disruption [79-82], 
apoptosis [41,51-55], and proliferation [47,97], so control of viral load might 
plausibly be expected to be associated with improved responses to PPV. However,  it 
is not clear that depletion in switched and MZM memory populations is restored by 
ART (and thus effective viral control) [90,116,118,119], which may be consistent 
with our findings, albeit in relatively small cohorts, that viraemia at the time of 
sampling does not appear to impact on the immune response to PPS in HIV infected 
individuals.  
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There was some suggestion in my data of poorer immune response in the vertically 
infected cohort, compared to the horizontally HIV-infected individuals. This may be 
related to the deficiency of both marginal zone and switched memory populations 
demonstrated in the vertically, but not horizontally infected, population (discussed in 
Chapter 3), and may be related to HIV infection during a period of critical immune 
development in early childhood, when primary exposure to S. pneumoniae is likely 
to have taken place. HIV viraemia at this time may have resulted in early damage to 
the immune repertoire, including VH3 gene bearing lineages [212], resulting in 
generation of poor quality clones responding to pneumococcal antigens following 
early exposure or colonisation. If the responding cells to PPV are predominantly 
those induced through natural infection, it would be unsurprising that neonatal 
infection has a greater impact on response to PPV in adulthood compared to in adult-
acquired infection.  This hypothesis may be consistent with the finding that early 
control of viraemia in the vertically infected cohort seemed, in this work, to be 
associated with an improved and potentially clinically relevant serological response 
to the PPV vaccine at 1 year, for both IgM and IgG. This is consistent with data from 
Pensieroso et al. [177], which showed relatively preserved anti-pneumococcal titres 
in those children started on ART before one year of age.  
The slightly older age of the horizontally infected cohort, compared to the vertically 
infected participants, may also be relevant to the apparent slight difference in 
antibody concentrations demonstrated. One study [150] has shown that for many 
serotypes of pneumococcal polysaccharide capsule, there is a marked increase in 
baseline antibody concentration in those aged older than 20 years, compared to 
younger individuals. In addition, the vertically infected group were primarily of 
Black African ethnicity, and the horizontally infected group of mixed ethnicity. 
Some studies have shown increased rates of pneumococcal disease in those of 
African-American race [304]. It has been postulated that this may be due to limited 
IgG antibody response to pneumococcal capsular polysaccharides in these 
populations [306,334]. One recent study, however, found no significant difference in 
antibody responses to pneumococcal challenge, in the context of revaccination, 
between those of African American and Caucasian ethnicity [335].   
No data was collected regarding prior exposure to Pnc, either by swabbing to assess 
colonisation, or by assessment of household controls to attempt to control for this 
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variable. Childhood environment may impact on exposure (by colonisation or non-
invasive infection, such as otitis media); although data was not examined regarding 
childhood environment, a proportion of both groups were born outside the UK, and 
are thus likely to have Pnc exposure histories which are difficult to compare. 
Exposure history would have been useful, as prior exposure is likely to be important 
in determining baseline immunity, which in turn, is likely to play a role in 
determining subsequent immune responses to PPS. Samples at 28 days after 
immunisation were few in the HIV-infected cohorts (this did not coincide with a 
routine clinic visit for most patients and was thus poorly attended), meaning that 
limited conclusions could be drawn regarding the relationship of baseline and short 
term immune responses. However, my data show that in the case of both IgM and 
IgG anti-pneumococcal antibody, in controls and patients, baseline antibody 
concentrations may predict, to some extent, the subsequent long term response to 
PPV, suggesting that there may be an element of secondary “boosting” in both the 
IgM and IgG memory response. Existing data confirm that the longer term IgG 
response to PPV immunisation is predicted by pre-immunisation serotype specific 
serum IgG concentration [336] and suggests that the IgG response to PPV may be 
secondary in nature [292]. 
 
In addition, the role of baseline IgM in facilitating the subsequent adaptive responses 
was explored by comparing pre-immunisation IgM with post-immunisation IgG 
responses. My data suggests that baseline IgM concentration predicted not only the 
subsequent IgM response, but also the serotype-specific anti-pneumococcal IgG 
concentration a year after administration of PPV vaccine in the vertically infected 
cohort. This suggests that the pre-existing presence of IgM memory, generated by 
the marginal zone compartment, may be relevant in promoting subsequent 
production of high affinity IgG [189,190,337]. Interestingly, this relationship 
between baseline IgM and later IgG production was only manifest in the vertically 
infected cohort in this study. This does not seem to be related to the low pre-existing 
IgM levels in this cohort per se, as healthy control subjects with low baseline IgM 
concentrations showed no correlation with post-immunisation IgG concentrations. 
The correlation seen in the vertically infected patients may be related to the marginal 
zone deficit seen only in this cohort (discussed in Chapter 3), as the marginal zone B 
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cells are believed to account for production of least part of the pre-existing IgM. 
Those vertically infected patients with baseline IgM concentrations below 0.35µg/ml 
were indeed shown to have lower percentages of MZM B cells than those with 
higher IgM concentrations. 
In conclusion, this work shows that HIV-infected young adults have both impaired 
natural immunity and diminished serological response to PPV vaccine compared to 
healthy controls. Vertically infected individuals may fare worse, perhaps because of 
duration of infection or depletion of MZM during critical stages of immune 
development. Early ART may limit the impaired responses observed in this study.  
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Chapter 5. Discussion  
5.1 Summary of findings and context 
 
This study is, to my knowledge, the first direct comparison of a cohort of vertically 
HIV-infected individuals with a cohort of similarly aged horizontally infected 
patients. It is also the first study to focus specifically on disturbance of peripheral 
blood B cell subpopulations and humoral immunity to pneumococcal 
polysaccharides in vertically infected HIV-infected individuals older than 12 years. I 
have showed that HIV infection was associated with derangement of B cell 
subpopulations, with expansion of abnormally activated and exhausted populations, 
and evidence of an increase in B cell apoptosis and altered B cell trafficking. 
Memory B cell populations were reduced in the vertically infected population and, as 
previously reported in paediatric cohorts [202], this was most apparent when viral 
load was controlled. HIV infection was also associated with impaired humoral 
immunity to PPS affecting both natural and vaccine induced immunity.  
 
Although these findings are broadly consistent with existing literature, showing 
increased immature, activated and exhausted cell populations in both adults 
[53,54,59,90,119,124,126,262] and children [125,200] and impaired natural and 
vaccine-induced immunity to Pnc [80,119,172-174,181,183,300-303,305], it is 
challenging to compare our findings directly with those reported elsewhere. Previous 
studies have included either adults, presumably infected by the horizontal route and 
considerably older than the cohort investigated here, or children, presumably 
infected by the vertically infected route, but of a younger age group than those 
considered here (usually aged younger than 12-15 years).  
In this study, the vertically infected cohort showed a reduction in both marginal zone 
and switched B cell memory, which was not seen in those who acquired their HIV 
infection in adulthood. This, taken with the trend towards poorer generation of 
serological memory, may suggest that the vertically infected cohort suffers greater 
reduction in the ability to generate and sustain immunological memory than their 
horizontally infected counterparts. Depletion of marginal zone memory may be 
particularly important: there is evidence from our data (in the vertically infected 
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cohort) and from others [336] that baseline IgM immunity, which is likely to be 
partly of marginal zone type, may also predict the ability to recruit an effective 
switched memory response.  
The deficit of marginal zone and switched memory cells in vertically infected young 
adults compared to those infected by the horizontal route may be a result of any or 
all of several differences between the two groups. The vertically and horizontally 
infected groups have not only a different route, but also a different duration, of 
infection. There is no existing data examining the impact of route of infection per se 
on immunity and it is impossible to examine this factor in isolation. Duration of 
infection may be important: existing literature [52,193] suggests that treatment early 
in the infection may be beneficial, perhaps suggesting that longer standing, untreated 
HIV disease has more significant deleterious effects. Certainly, damage to lymphoid 
tissue in long standing infection has been shown [252], and might, plausibly, be 
more extensive in those patients who have been infected since birth than in those 
recently infected, resulting in impairment of function required for generation and 
maintenance of effective B cell memory.  
Perhaps most importantly, the timing of HIV infection, in relation to immune 
development, is drastically different in vertically and horizontally infected patients. 
Those young adults infected by the horizontal route have acquired their HIV 
infection in the context of a mature and presumably normal immune system, whereas 
those vertically infected have endured HIV viraemia during a critical window of 
early immunological development, which may have had significant impact on their 
ability to generate healthy and normal immunological repertoire and function. Early 
childhood is the time when many important pathogens are encountered for the first 
time, and the quality of the immune responses generated are likely to be important 
for lifelong immune function [225]; impairment of generation of normal early-life 
immune responses, as may occur in childhood HIV infection, may thus have long 
lasting impact on immune competence.  
In addition to these differences which are inherent to the two cohorts, it is important 
to acknowledge demographic differences between the two HIV-infected groups, 
which were not perfectly matched in terms of either age (horizontally infected 
patients were slightly older), nor ethnicity. However, as discussed previously, there 
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is little data to support a significant role for these factors in determining the status of 
the B cell compartment either in healthy or HIV-infected individuals, and it is 
unlikely that these factors explain the differences seen.  
 
Despite the potentially deleterious timing and significantly longer duration of 
infection in the vertically infected cohort, there are some encouraging findings in this 
group. The increased naïve B cell population in the vertically infected patients, 
compared to those infected in adulthood, may, perhaps, represent an increased 
capacity for restoration and regeneration, perhaps as a result of slightly younger age, 
or perhaps resulting from achievement of a new immunological “steady state” due to 
long standing infection. Reconstitution of damaged cell pools has been shown in the 
context of T cell recovery in young HIV-infected children, as discussed in Chapter 1. 
Vertically infected patients also showed a smaller increase in immature and 
abnormally activated B cell populations than did their horizontally infected 
counterparts, which may further suggest resilience to the dynamic changes of HIV 
infection, consistent with data showing that the immune system may remain 
relatively well preserved in even longstanding asymptomatic HIV infection [232], 
and encouraging long term outcomes have been predicted [233]. Lastly, although 
natural and vaccine-induced immunity was reduced in both patient groups compared 
to healthy controls, it is perhaps reassuring that the difference between the vertically 
and horizontally infected groups was slight, possibly indicating relatively little 
impact of their long duration of infection on their capacity to generate and maintain 
humoral immunity, at least in the context of pneumococcal infection. 
 
My data suggests that early and sustained control of HIV viraemia may protect 
against both HIV-related derangement to B cell subpopulations and impairment of 
the serological response to PPV immunisation. This is consistent with other data, in 
younger children, showing benefit of early initiation of ART [177], and might 
perhaps have been more pronounced in our study had it been possible to examine the 
impact of viral control in the first year of life, a distinction prevented by the small 
sample size in this study. Currently, ART in vertically infected infants in Europe is 
initiated at birth, but in children presenting after the first year of life, initiation of 
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treatment is guided by clinical progression or CD4
+
 depletion [234]. Globally, World 
Health Organisation guidelines recommend treatment of all children under 5 years of 
age [235] and the guidelines in Europe are currently being revised and may suggest 
treatment for all children under 3 years old (personal communication with Nigel 
Klein). This work may be of importance in contributing to an understanding of the 
importance of ART in early life in vertically infected children, in order to preserve 
the B cell compartment of the immune system for the future.  
5.2 Limitations of this work 
 
Variation in immunological parameters, even amongst healthy individuals, means 
that large study populations are required to robustly demonstrate disease-related 
differences. This work was limited by small patient numbers, inevitable due to the 
relative paucity of young adults aged 12-25 years in the UK infected with HIV by 
either the vertical or horizontal route. The sample sizes in this study, however, are 
not dissimilar from that studied in other published work. Recent local endeavours to 
ensure patient immunisations were up to date, including with PPV/PCV, as a result 
of the recent H1N1 influenza epidemic in 2009, reduced patients eligible for 
recruitment still further, as only those with no history of prior PPV/PCV were 
eligible for inclusion in the study.  Poor clinic attendance (with “did not attend” rates 
for follow up appointments above 80% for some patient groups; personal 
communication) resulted in limited sample size for follow-up data. Due to limited 
numbers of patients suitable for recruitment, it was not possible to ensure 
homogeneity of patient cohorts in terms of antiretroviral status and history, clinical 
status and viral load. Potentially confounding differences between groups in terms of 
ethnicity and age were also unavoidable due to the epidemiological patterns seen in 
these patient groups in the UK. Historical data regarding viral control was difficult to 
obtain and was not available for all patients, particularly those who had recently 
arrived in the UK.  
Clinical protection against pneumococcal disease is a function of both antibody 
concentration and function. Analysis in this study of generation of serological 
memory was quantitative only; there is significant evidence in the literature for 
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impact of HIV infection on function of antibodies [314,315] in addition to the 
reduction in serum concentrations and this will be explored in future work.  
The statistical analysis of data presented in this thesis is comprehensively described. 
However it is acknowledged that multiple comparisons were performed on the data 
set. Whilst a Bonferroni correction was not applied, individual p values are given 
where relevant, to enable the reader to evaluate the likely probability of significance.  
This was a cross-sectional study, with follow up limited to one year after 
immunisation. Further longitudinal data regarding this vertically infected cohort of 
young adults will be important in determining their long term prognosis and 
requirements for clinical care. 
5.3 Importance of this work  
 
This study is the first to interrogate the B cell immunity of this growing group of 
vertically HIV-infected young adults and to perform a direct comparison with young 
adults infected in adulthood by the horizontal route. 
While it may be relatively reassuring that the vertically infected cohort, despite their 
longer duration of infection, show B cell phenotype and function broadly similar to 
the horizontally infected group (perhaps as a result of good clinical care and access 
to ART), the deficits seen in the memory compartment are concerning. Currently, 
once transitioned from paediatric care, these young adults are treated alongside other 
young adults infected by the horizontal route, according to the same clinical 
guidelines. These data, however, suggests that the vertically infected young adults 
are, in fact, a distinct immunological group from their horizontally infected 
counterparts and may exhibit a different profile of clinical risk, particularly to 
encapsulated organisms such as S. pneumoniae. This patient group may benefit 
particularly from appropriate immunisation and surveillance, as they age and as their 
HIV infection progresses.  
The trend towards relative sparing of B cell subpopulations and vaccine-induced Pnc 
immunity in those with early-life viral control in this study also suggests the 
importance of early effective ART in mitigating against HIV-related B cell 
derangements. While early ART is already part of existing guidelines for those 
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infants diagnosed at birth [234], it is not currently recommended for those children 
diagnosed after the first year of life in all guidelines, who may, in fact, benefit from 
early viral control.  
5.4 Conclusions and future directions 
 
These data suggest that vertically and horizontally infected young adults appear to be 
immunologically distinct populations in the context of humoral immunity and 
specifically pneumococcal immunity.   
Studies are already underway within our own group to analyse B cell 
immunoglobulin repertoire by CDR spectratyping to establish whether defects seen 
in the vertically infected population may result from a failure to establish good 
quality immune repertoire, perhaps due to viraemia at a critical window of immune 
development. Future work in this area should aim to examine larger patient cohorts, 
with greater homogeneity in terms of viral control and previous antiretroviral 
exposure and improved matching for ethnicity, to reduce the potentially confounding 
effects of these variables. As the cohort of vertically infected patients grows older, 
better intergroup matching for age with horizontally infected patients may also be 
possible. Further studies should also address deficits in functional, as well as 
quantitative, serological memory. It would also be of interest to examine specific 
memory B cell responses, which are suggested by some data in HIV-infected 
children, in the context of influenza vaccination, to be a better correlate of vaccine-
induced protection that antibody concentration [338]. 
 
Although it is not possible to control for duration of infection, which is an inherent 
difference between the patient cohorts, it may be possible to further elucidate the 
mechanism(s) underlying differences in the cohorts. Biopsy of lymphoid tissue, 
although not feasible for ethical reasons, would also be useful to identify 
contribution of fibrosis secondary to disease duration to the impaired B cell 
compartment in vertically infected patients.  
Further work of this kind will be important in determining the nature and extent of 
immunological differences between these two cohorts of vertically and horizontally 
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infected young adults and in elucidating their underlying mechanisms. This may be 
ultimately relevant in optimising clinical management.  
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